Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
24,400 | 2020-09-11 00:00:00 UTC | Is AbbVie Stock a Buy? | ABBV | https://www.nasdaq.com/articles/is-abbvie-stock-a-buy-2020-09-11 | null | null | As the youngest of the pharma juggernauts, AbbVie (NYSE: ABBV) is an exciting company because of its impressive size and lineup of popular pharmaceutical and biological products. Since its spinoff from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has built an attractive portfolio of drugs while exploring promising p... | As the youngest of the pharma juggernauts, AbbVie (NYSE: ABBV) is an exciting company because of its impressive size and lineup of popular pharmaceutical and biological products. Since its spinoff from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has built an attractive portfolio of drugs while exploring promising p... | AbbVie expects to make a total of $48 billion in total revenue this year, including sales from its new Allergan products. According to AbbVie's second quarter earnings report, Allergan's portfolio brought in roughly $1.73 billion. As the youngest of the pharma juggernauts, AbbVie (NYSE: ABBV) is an exciting company bec... | AbbVie expects to make a total of $48 billion in total revenue this year, including sales from its new Allergan products. AbbVie's pipeline will make 2021 exciting for investors Given that AbbVie is actively developing a plethora of new drugs while continuing development of Allergan's products, other streams of income ... | First, AbbVie's $63 billion acquisition of Allergan was finalized in May, but the deal's impact on AbbVie's bottom line is far from clear. According to AbbVie's second quarter earnings report, Allergan's portfolio brought in roughly $1.73 billion. As the youngest of the pharma juggernauts, AbbVie (NYSE: ABBV) is an exc... |
24,401 | 2020-09-08 00:00:00 UTC | S.Korea's Celltrion to begin commercial production of COVID-19 antibody drug | ABBV | https://www.nasdaq.com/articles/s.koreas-celltrion-to-begin-commercial-production-of-covid-19-antibody-drug-2020-09-08 | null | null | By Sangmi Cha
SEOUL, Sept 8 (Reuters) - South Korea's Celltrion Inc 068270.KS will begin commercial production of its experimental treatment for COVID-19 this month, it said on Tuesday, as it pushes ahead with clinical trials of the antibody drug.
The company said it planned to make a request soon to regulators for eme... | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. By Sangmi Cha SEOUL, Sept 8 (Reuters) - South Korea's Celltrion Inc 068270.KS will begin commercial production of its experimental treatment for COVID-19 this month, it said o... | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. By Sangmi Cha SEOUL, Sept 8 (Reuters) - South Korea's Celltrion Inc 068270.KS will begin commercial production of its experimental treatment for COVID-19 this month, it said o... | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. By Sangmi Cha SEOUL, Sept 8 (Reuters) - South Korea's Celltrion Inc 068270.KS will begin commercial production of its experimental treatment for COVID-19 this month, it said o... | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. The treatment became the country's first COVID-19 antibody drug to be tested on humans after receiving regulatory approval in July for clinical trials. "We have confirmed the ... |
24,402 | 2020-09-04 00:00:00 UTC | AbbVie Partners With I-Mab for Cancer Drug | ABBV | https://www.nasdaq.com/articles/abbvie-partners-with-i-mab-for-cancer-drug-2020-09-04 | null | null | AbbVie (NYSE: ABBV) has signed a collaboration agreement with Chinese clinical-stage biotechnology company I-Mab (NASDAQ: IMAB) for the development and commercialization of lemzoparlimab, a monoclonal antibody in early-stage clinical testing that could be used to treat various cancers. The antibody targets CD47, a prot... | AbbVie (NYSE: ABBV) has signed a collaboration agreement with Chinese clinical-stage biotechnology company I-Mab (NASDAQ: IMAB) for the development and commercialization of lemzoparlimab, a monoclonal antibody in early-stage clinical testing that could be used to treat various cancers. AbbVie will get an exclusive lice... | AbbVie (NYSE: ABBV) has signed a collaboration agreement with Chinese clinical-stage biotechnology company I-Mab (NASDAQ: IMAB) for the development and commercialization of lemzoparlimab, a monoclonal antibody in early-stage clinical testing that could be used to treat various cancers. The collaboration potentially inv... | AbbVie (NYSE: ABBV) has signed a collaboration agreement with Chinese clinical-stage biotechnology company I-Mab (NASDAQ: IMAB) for the development and commercialization of lemzoparlimab, a monoclonal antibody in early-stage clinical testing that could be used to treat various cancers. On a conference call with analyst... | The collaboration potentially involves exploring the combination of lemzoparlimab with AbbVie's blood cancer drug Venclexta. AbbVie (NYSE: ABBV) has signed a collaboration agreement with Chinese clinical-stage biotechnology company I-Mab (NASDAQ: IMAB) for the development and commercialization of lemzoparlimab, a monoc... |
24,403 | 2020-09-04 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Domo Inc, CureVac NV, Cooper Companies, Wayfair Inc | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-domo-inc-curevac-nv-cooper-companies-wayfair-inc-2020-09-04 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes extended declines on Friday, with the Nasdaq on track for its worst two-day fall since March as technology stocks sold off again,... | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes extended declines on Friday, with the Nasdaq on track for its worst two-day fall since March as technology stocks sold off again,... | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes extended declines on Friday, with the Nasdaq on track for its worst two-day fall since March as technology stocks sold off again,... | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes extended declines on Friday, with the Nasdaq on track for its worst two-day fall since March as technology stocks sold off again,... | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes extended declines on Friday, with the Nasdaq on track for its worst two-day fall since March as technology stocks sold off again,... |
24,404 | 2020-09-04 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Apple Inc, Tesla Inc, PolyMet Mining Corp, Seelos Therapeutics | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-apple-inc-tesla-inc-polymet-mining-corp-seelos-therapeutics | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 rose shortly after the opening bell on Friday after a brutal selloff in the previous session as data showed U.S. unemployment rate dropped more ... | The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 8.8% ** Discover Financial Services , up 5.5% ** Broadcom Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Nvidia Corp , down 5.8% ** Paypal Holdings Inc , down 5.4% ** Dexcom Inc , down 4.8% The top three NYSE .PG.N percent... | The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 8.8% ** Discover Financial Services , up 5.5% ** Broadcom Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Nvidia Corp , down 5.8% ** Paypal Holdings Inc , down 5.4% ** Dexcom Inc , down 4.8% The top three NYSE .PG.N percent... | The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 8.8% ** Discover Financial Services , up 5.5% ** Broadcom Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Nvidia Corp , down 5.8% ** Paypal Holdings Inc , down 5.4% ** Dexcom Inc , down 4.8% The top three NYSE .PG.N percent... | The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 8.8% ** Discover Financial Services , up 5.5% ** Broadcom Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Nvidia Corp , down 5.8% ** Paypal Holdings Inc , down 5.4% ** Dexcom Inc , down 4.8% The top three NYSE .PG.N percent... |
24,405 | 2020-09-04 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-I-Mab, AnPac Bio-Medical Science, DPW Holdings | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-i-mab-anpac-bio-medical-science-dpw-holdings-2020-09-04 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 was set for a higher open on Friday following a brutal selloff in the previous session as a drop in the unemployment rate offset a slide in tech... | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was set for a higher open on Friday following a brutal selloff in the previous session as a drop in the unemployment rate offset a slide in tech... | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was set for a higher open on Friday following a brutal selloff in the previous session as a drop in the unemployment rate offset a slide in tech... | S&P 500 e-minis ESc1 were down 0.13% at 3,457, while Nasdaq 100 e-minis NQc1 were down 1.24% at 11,654. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Kensington Capital Acquisition Corp , up 16.9% ** Clearwater Paper Corp , up 15.0% ** Permianville Royalty Trust , up 11.1% The top three NYSE percentage l... | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was set for a higher open on Friday following a brutal selloff in the previous session as a drop in the unemployment rate offset a slide in tech... |
24,406 | 2020-09-04 00:00:00 UTC | AbbVie to develop and sell China-based I-Mab's cancer drug | ABBV | https://www.nasdaq.com/articles/abbvie-to-develop-and-sell-china-based-i-mabs-cancer-drug-2020-09-04 | null | null | Adds financial details, shares, background
Sept 4 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's IMAB.O cancer drug, the companies said on Friday.
The U.S.-listed shares of I-Mab jumped 18.8% to $42.5 before the opening bell.
The... | Adds financial details, shares, background Sept 4 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's IMAB.O cancer drug, the companies said on Friday. AbbVie will pay an additional $1.74 billion in milestone payments for lemzoparlima... | Adds financial details, shares, background Sept 4 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's IMAB.O cancer drug, the companies said on Friday. The agreement is the latest push by AbbVie into cancer therapies after its June co... | Adds financial details, shares, background Sept 4 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's IMAB.O cancer drug, the companies said on Friday. The agreement is the latest push by AbbVie into cancer therapies after its June co... | Adds financial details, shares, background Sept 4 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's IMAB.O cancer drug, the companies said on Friday. The agreement is the latest push by AbbVie into cancer therapies after its June co... |
24,407 | 2020-09-04 00:00:00 UTC | Like Dividends? I Bet You'll Love These 2 Stocks | ABBV | https://www.nasdaq.com/articles/like-dividends-i-bet-youll-love-these-2-stocks-2020-09-04 | null | null | The "Oracle of Omaha," Warren Buffett, has famously been quoted as saying, "Price is what you pay. Value is what you get." Dividend stocks are a tried-and-true way of adding value to your portfolio -- when a company pays a generous dividend, this can be a sign of its potential as a reliable long-term investment. High d... | Factoring in the Allergen acquisition, AbbVie anticipates diluted earnings per share (EPS) under generally accepted accounting principles (GAAP) to hit somewhere in the range of $4.12 to $4.22 for the whole of 2020. AbbVie Biopharmaceutical giant AbbVie (NYSE: ABBV) is among the crème de la crème of stocks known as Div... | AbbVie Biopharmaceutical giant AbbVie (NYSE: ABBV) is among the crème de la crème of stocks known as Dividend Aristocrats. To be listed on the S&P 500's Dividend Aristocrat index, a stock must boost its dividend every year for at least 25 years in a row; AbbVie's history as part of Abbott Laboratories (NYSE: ABT), from... | AbbVie Biopharmaceutical giant AbbVie (NYSE: ABBV) is among the crème de la crème of stocks known as Dividend Aristocrats. To be listed on the S&P 500's Dividend Aristocrat index, a stock must boost its dividend every year for at least 25 years in a row; AbbVie's history as part of Abbott Laboratories (NYSE: ABT), from... | To be listed on the S&P 500's Dividend Aristocrat index, a stock must boost its dividend every year for at least 25 years in a row; AbbVie's history as part of Abbott Laboratories (NYSE: ABT), from which it spun off in 2013, is included there. AbbVie Biopharmaceutical giant AbbVie (NYSE: ABBV) is among the crème de la ... |
24,408 | 2020-09-04 00:00:00 UTC | AbbVie To License I-Mab's Anti-CD47 Monoclonal Antibody Lemzoparlimab | ABBV | https://www.nasdaq.com/articles/abbvie-to-license-i-mabs-anti-cd47-monoclonal-antibody-lemzoparlimab-2020-09-04 | null | null | (RTTNews) - AbbVie (ABBV) and I-Mab (IMAB) have signed a global collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. AbbVie will pay I-Mab $180 million in an upfront paymen... | (RTTNews) - AbbVie (ABBV) and I-Mab (IMAB) have signed a global collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. Upon commercialization of lemzoparlimab, AbbVie will al... | (RTTNews) - AbbVie (ABBV) and I-Mab (IMAB) have signed a global collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. AbbVie will pay I-Mab $180 million in an upfront paymen... | (RTTNews) - AbbVie (ABBV) and I-Mab (IMAB) have signed a global collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. AbbVie will pay I-Mab $180 million in an upfront paymen... | (RTTNews) - AbbVie (ABBV) and I-Mab (IMAB) have signed a global collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. AbbVie will pay I-Mab $180 million in an upfront paymen... |
24,409 | 2020-09-01 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Quest Diagnostics, Murphy USA Inc, Intercept Pharmaceuticals | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-quest-diagnostics-murphy-usa-inc-intercept-pharmaceuticals | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 and the Nasdaq hit new highs on Tuesday with the tech-heavy index boosted by Apple and Zoom Video, while better-than-expected U.S. manufacturing... | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 5.2% ** Albemarle Corp , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 4.8% ** Regeneron Pharmaceuticals Inc , down 4.5% ** Abbvie Inc , down 4.3% The top three NYSE .PG.N percentage gainers: **... | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 5.2% ** Albemarle Corp , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 4.8% ** Regeneron Pharmaceuticals Inc , down 4.5% ** Abbvie Inc , down 4.3% The top three NYSE .PG.N percentage gainers: **... | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 5.2% ** Albemarle Corp , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 4.8% ** Regeneron Pharmaceuticals Inc , down 4.5% ** Abbvie Inc , down 4.3% The top three NYSE .PG.N percentage gainers: **... | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 5.2% ** Albemarle Corp , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 4.8% ** Regeneron Pharmaceuticals Inc , down 4.5% ** Abbvie Inc , down 4.3% The top three NYSE .PG.N percentage gainers: **... |
24,410 | 2020-09-01 00:00:00 UTC | Notable Tuesday Option Activity: CSCO, ABBV, MA | ABBV | https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-csco-abbv-ma-2020-09-01 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Cisco Systems Inc (Symbol: CSCO), where a total of 150,103 contracts have traded so far, representing approximately 15.0 million underlying shares. That amounts to about 64.2% of CSCO's average daily trading volume o... | Especially high volume was seen for the $95 strike call option expiring September 18, 2020, with 4,570 contracts trading so far today, representing approximately 457,000 underlying shares of ABBV. Below is a chart showing CSCO's trailing twelve month trading history, with the $44 strike highlighted in orange: AbbVie In... | Below is a chart showing CSCO's trailing twelve month trading history, with the $44 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 31,758 contracts thus far today. That number of contracts represents approximately 3.2 million underlying shares, working out to a sizeable 49% of A... | Below is a chart showing CSCO's trailing twelve month trading history, with the $44 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 31,758 contracts thus far today. That number of contracts represents approximately 3.2 million underlying shares, working out to a sizeable 49% of A... | Below is a chart showing MA's trailing twelve month trading history, with the $360 strike highlighted in orange: For the various different available expirations for CSCO options, ABBV options, or MA options, visit StockOptionsChannel.com. Below is a chart showing CSCO's trailing twelve month trading history, with the $... |
24,411 | 2020-09-01 00:00:00 UTC | Tuesday's ETF with Unusual Volume: IWX | ABBV | https://www.nasdaq.com/articles/tuesdays-etf-with-unusual-volume%3A-iwx-2020-09-01 | null | null | The iShares Russell Top 200 Value ETF is seeing unusually high volume in afternoon trading Tuesday, with over 185,000 shares traded versus three month average volume of about 93,000. Shares of IWX were down about 0.2% on the day.
Components of that ETF with the highest volume on Tuesday were General Electric, trading d... | Walmart is the component faring the best Tuesday, higher by about 6% on the day, while Abbvie is lagging other components of the iShares Russell Top 200 Value ETF, trading lower by about 4.6%. The iShares Russell Top 200 Value ETF is seeing unusually high volume in afternoon trading Tuesday, with over 185,000 shares tr... | Walmart is the component faring the best Tuesday, higher by about 6% on the day, while Abbvie is lagging other components of the iShares Russell Top 200 Value ETF, trading lower by about 4.6%. The iShares Russell Top 200 Value ETF is seeing unusually high volume in afternoon trading Tuesday, with over 185,000 shares tr... | Walmart is the component faring the best Tuesday, higher by about 6% on the day, while Abbvie is lagging other components of the iShares Russell Top 200 Value ETF, trading lower by about 4.6%. The iShares Russell Top 200 Value ETF is seeing unusually high volume in afternoon trading Tuesday, with over 185,000 shares tr... | Walmart is the component faring the best Tuesday, higher by about 6% on the day, while Abbvie is lagging other components of the iShares Russell Top 200 Value ETF, trading lower by about 4.6%. Components of that ETF with the highest volume on Tuesday were General Electric, trading down about 0.2% with over 36.4 million... |
24,412 | 2020-09-01 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Abbvie Inc, Hawaiian Holdings, Zoom Video Communications | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-abbvie-inc-hawaiian-holdings-zoom-video-communications-2020 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street climbed on Tuesday as gains in Apple and Zoom Video shares propelled the tech-heavy Nasdaq to record highs, while better-than-expected U.S. manu... | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 4.1% ** Broadcom Inc , up 3.8% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 5% ** Abbvie Inc , down 4.2% ** Regeneron Pharmaceuticals Inc , down 4.2% The top three NYSE .PG.N percentage gainers: ** Lib... | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 4.1% ** Broadcom Inc , up 3.8% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 5% ** Abbvie Inc , down 4.2% ** Regeneron Pharmaceuticals Inc , down 4.2% The top three NYSE .PG.N percentage gainers: ** Lib... | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 4.1% ** Broadcom Inc , up 3.8% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 5% ** Abbvie Inc , down 4.2% ** Regeneron Pharmaceuticals Inc , down 4.2% The top three NYSE .PG.N percentage gainers: ** Lib... | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 4.1% ** Broadcom Inc , up 3.8% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 5% ** Abbvie Inc , down 4.2% ** Regeneron Pharmaceuticals Inc , down 4.2% The top three NYSE .PG.N percentage gainers: ** Lib... |
24,413 | 2020-09-01 00:00:00 UTC | U.S. House Oversight Committee to subpoena AbbVie in drug-pricing probe | ABBV | https://www.nasdaq.com/articles/u.s.-house-oversight-committee-to-subpoena-abbvie-in-drug-pricing-probe-2020-09-01 | null | null | Adds AbbVie comment
Sept 1 (Reuters) - The U.S. House Oversight Committee on Tuesday decided to subpoena AbbVie Inc ABBV.N to seek documents on the drugmaker's blockbuster treatments, Humira and Imbruvica, as part of its investigation into drug-pricing practices.
The committee began the probe last year and had sought i... | Adds AbbVie comment Sept 1 (Reuters) - The U.S. House Oversight Committee on Tuesday decided to subpoena AbbVie Inc ABBV.N to seek documents on the drugmaker's blockbuster treatments, Humira and Imbruvica, as part of its investigation into drug-pricing practices. "Although most of the drug companies we are examining ha... | Adds AbbVie comment Sept 1 (Reuters) - The U.S. House Oversight Committee on Tuesday decided to subpoena AbbVie Inc ABBV.N to seek documents on the drugmaker's blockbuster treatments, Humira and Imbruvica, as part of its investigation into drug-pricing practices. "After more than 18 months, AbbVie has demonstrated its ... | Adds AbbVie comment Sept 1 (Reuters) - The U.S. House Oversight Committee on Tuesday decided to subpoena AbbVie Inc ABBV.N to seek documents on the drugmaker's blockbuster treatments, Humira and Imbruvica, as part of its investigation into drug-pricing practices. "After more than 18 months, AbbVie has demonstrated its ... | Adds AbbVie comment Sept 1 (Reuters) - The U.S. House Oversight Committee on Tuesday decided to subpoena AbbVie Inc ABBV.N to seek documents on the drugmaker's blockbuster treatments, Humira and Imbruvica, as part of its investigation into drug-pricing practices. "After more than 18 months, AbbVie has demonstrated its ... |
24,414 | 2020-09-01 00:00:00 UTC | 2 Embarrassingly Cheap Dividend Stocks | ABBV | https://www.nasdaq.com/articles/2-embarrassingly-cheap-dividend-stocks-2020-09-01 | null | null | Investing in sturdy dividend stocks is a fantastic way to diversify your portfolio and collect some extra cash. If you invest in companies with a historically robust (and growing) dividend and stable balance sheet, you could enjoy a stream of secondary income that can be used to buy additional shares, save, or put towa... | Gilead had hoped that its potential rheumatoid arthritis (RA) treatment, filgotinib, and its unique profile would provide RA patients better results than some of the bigger drugs on the market, which include Johnson & Johnson's Remicade, AbbVie's Humira, and Amgen's Enbrel. If you invest in companies with a historicall... | Gilead had hoped that its potential rheumatoid arthritis (RA) treatment, filgotinib, and its unique profile would provide RA patients better results than some of the bigger drugs on the market, which include Johnson & Johnson's Remicade, AbbVie's Humira, and Amgen's Enbrel. Although biopharmaceutical leader Gilead Scie... | Gilead had hoped that its potential rheumatoid arthritis (RA) treatment, filgotinib, and its unique profile would provide RA patients better results than some of the bigger drugs on the market, which include Johnson & Johnson's Remicade, AbbVie's Humira, and Amgen's Enbrel. Large-cap pharmaceutical company Bristol Myer... | Gilead had hoped that its potential rheumatoid arthritis (RA) treatment, filgotinib, and its unique profile would provide RA patients better results than some of the bigger drugs on the market, which include Johnson & Johnson's Remicade, AbbVie's Humira, and Amgen's Enbrel. Before this use expansion, Veklury was only a... |
24,415 | 2020-09-01 00:00:00 UTC | Forget Johnson & Johnson, AbbVie Is a Better Dividend Stock | ABBV | https://www.nasdaq.com/articles/forget-johnson-johnson-abbvie-is-a-better-dividend-stock-2020-09-01 | null | null | Dividend stocks are great for long-term investors who want to sit back and watch secondary income accumulate. Dividend investing can be a great way to supplement returns, especially over longer periods of time once you've accumulated a nice number of paying stocks in your portfolio. In the midst of the biggest recessio... | The deal with Allergan renders AbbVie's business opportunities safer, and makes room for the company to continue growing its dividend payouts at a high rate. An investor's job is made trickier by the fact that both of these healthcare stocks appear similar in their returns this year: ABBV data by YCharts Neither compan... | AbbVie, however, pays a quarterly dividend of $1.18, which annually yields over 5% at current share prices. AbbVie released its second-quarter results on July 31 for the period ended June 30. But perhaps there's an even better option for dividend investors in pharmaceutical company AbbVie (NYSE: ABBV). | Here's why: AbbVie's dividend yield is much higher -- and likely to stay that way Today, J&J pays its shareholders a quarterly dividend of $1.01 for an annual yield of 2.6%, which is well above the S&P 500 average of 2%. Unless there's a significant change in dividend policies from either of these two companies, it is ... | Here's why: AbbVie's dividend yield is much higher -- and likely to stay that way Today, J&J pays its shareholders a quarterly dividend of $1.01 for an annual yield of 2.6%, which is well above the S&P 500 average of 2%. AbbVie, however, pays a quarterly dividend of $1.18, which annually yields over 5% at current share... |
24,416 | 2020-08-28 00:00:00 UTC | These 3 Dividend Stocks Could Bring You an Extra $100 a Month | ABBV | https://www.nasdaq.com/articles/these-3-dividend-stocks-could-bring-you-an-extra-%24100-a-month-2020-08-28 | null | null | One of the benefits of investing in dividend stocks it that they can generate recurring income. Whether it's to help pay bills or boost your savings, it's not hard to find a use for some extra cash. But many dividend stocks pay on a quarterly basis, meaning you'll need to wait three months for each payout to flow throu... | AbbVie Drug manufacturer AbbVie (NYSE: ABBV) is known for its blockbuster, Humira, which treats rheumatoid arthritis and Crohn's disease among other conditions. With profit margins of at least 17% in each of the past five years and annual revenue rising from $20 billion in 2014 to $33.3 billion in 2019, AbbVie's busine... | AbbVie 5% $8,000 $100 February, May, August, November Unilever 3.1% $12,900 $100 March, June, September, December JPMorgan Chase 3.6% $11,100 $100 January, April, July, October Data source: AbbVie, Unilever, JPMorgan Chase. AbbVie Drug manufacturer AbbVie (NYSE: ABBV) is known for its blockbuster, Humira, which treats ... | AbbVie 5% $8,000 $100 February, May, August, November Unilever 3.1% $12,900 $100 March, June, September, December JPMorgan Chase 3.6% $11,100 $100 January, April, July, October Data source: AbbVie, Unilever, JPMorgan Chase. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock ... | An $8,000 investment in AbbVie would bring investors $400 for the year, or $100 every three months. AbbVie Drug manufacturer AbbVie (NYSE: ABBV) is known for its blockbuster, Humira, which treats rheumatoid arthritis and Crohn's disease among other conditions. With profit margins of at least 17% in each of the past fiv... |
24,417 | 2020-08-27 00:00:00 UTC | UroGen Pharma: Phase 2 APOLLO Clinical Trial Did Not Meet Primary Endpoint | ABBV | https://www.nasdaq.com/articles/urogen-pharma%3A-phase-2-apollo-clinical-trial-did-not-meet-primary-endpoint-2020-08-27 | null | null | (RTTNews) - Biopharmaceutical company UroGen Pharma Ltd. (URGN) said Thursday that the Phase 2 APOLLO clinical trial of a RTGel hydrogel formulation in combination with Botox (onabotulinumtoxinA) intravesical instillation in patients with overactive bladder (OAB) and urinary incontinence did not meet the primary endpoi... | The topline data from this trial reinforces that our RTGel technology could be combined with a substantial library of molecules to deliver therapy where dwell time may improve outcomes and we look forward to our continued collaboration with AbbVie as they develop their portfolio of toxin proteins," said Dr. Mark Schoen... | The agreement granted an exclusive worldwide license to Allergan plc, now an AbbVie company, to research, manufacture and commercialize pharmaceutical products formulated with an RTGel hydrogel formulation and clostridial toxins, including Botox. The license agreement enables the companies to continue exploration of th... | The topline data from this trial reinforces that our RTGel technology could be combined with a substantial library of molecules to deliver therapy where dwell time may improve outcomes and we look forward to our continued collaboration with AbbVie as they develop their portfolio of toxin proteins," said Dr. Mark Schoen... | The license agreement enables the companies to continue exploration of the RTGel hydrogel formulation in combination with AbbVie's portfolio of clostridial toxins in OAB and other patient populations. The topline data from this trial reinforces that our RTGel technology could be combined with a substantial library of m... |
24,418 | 2020-08-26 00:00:00 UTC | Is Gilead Sciences a Buy After Its Most Recent Roadblock? | ABBV | https://www.nasdaq.com/articles/is-gilead-sciences-a-buy-after-its-most-recent-roadblock-2020-08-26 | null | null | Gilead Sciences (NASDAQ: GILD) navigated the coronavirus market crash better than most. At one point, the biotech's antiviral drug, Veklury (remdesivir), was considered one of the most promising potential treatments for COVID-19. In May, the U.S. Food and Drug Administration (FDA) granted Veklury an Emergency Use Autho... | Some of the top-selling products that treat the condition include AbbVie's Humira, Johnson & Johnson's Remicade, and Amgen's Enbrel, among others. Gilead expects preliminary results from these studies in the first half of 2021, which means filgotinib won't earn regulatory approval until sometime next year at best. One ... | Some of the top-selling products that treat the condition include AbbVie's Humira, Johnson & Johnson's Remicade, and Amgen's Enbrel, among others. The FDA denied the approval of the company's treatment candidate, filgotinib, as a therapy for rheumatoid arthritis (RA). The COVID-19 treatment has received regulatory appr... | Some of the top-selling products that treat the condition include AbbVie's Humira, Johnson & Johnson's Remicade, and Amgen's Enbrel, among others. Gilead expects preliminary results from these studies in the first half of 2021, which means filgotinib won't earn regulatory approval until sometime next year at best. Note... | Some of the top-selling products that treat the condition include AbbVie's Humira, Johnson & Johnson's Remicade, and Amgen's Enbrel, among others. What's next for Gilead Sciences? During the fiscal year 2019, revenue from this segment came in at $2.9 billion, compared to $3.7 billion during the fiscal year 2018. |
24,419 | 2020-08-25 00:00:00 UTC | 6 Marijuana Stocks to Buy That Are Sticking In the Green | ABBV | https://www.nasdaq.com/articles/6-marijuana-stocks-to-buy-that-are-sticking-in-the-green-2020-08-25 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Investors searching for marijuana stocks to buy are looking to get green. So how can investors identify stocks that will “get green?” From investors’ perspective this should likely relate to price appreciation. However, there is no exact formula for price a... | With its dividend and well-run operations, ABBV stock is an excellent choice for investors looking to avoid volatile pure cannabis plays. AbbVie (NYSE:ABBV) GW Pharmaceuticals (NASDAQ:GWPH) Cresco Labs (OTCMKTS:CRLBF) GrowGeneration (NASDAQ:GRWG) Green Thumb Industries (OTCMKTS:GTBIF) Village Farms International (NASDA... | AbbVie (NYSE:ABBV) GW Pharmaceuticals (NASDAQ:GWPH) Cresco Labs (OTCMKTS:CRLBF) GrowGeneration (NASDAQ:GRWG) Green Thumb Industries (OTCMKTS:GTBIF) Village Farms International (NASDAQ:VFF) Let’s take a closer look at what makes each of these stocks worth your consideration. Marijuana Stocks to Buy: AbbVie (ABBV) ABBV) ... | AbbVie (NYSE:ABBV) GW Pharmaceuticals (NASDAQ:GWPH) Cresco Labs (OTCMKTS:CRLBF) GrowGeneration (NASDAQ:GRWG) Green Thumb Industries (OTCMKTS:GTBIF) Village Farms International (NASDAQ:VFF) Let’s take a closer look at what makes each of these stocks worth your consideration. Marijuana Stocks to Buy: AbbVie (ABBV) ABBV) ... | 10 Growth Stocks That Could Seriously Double Much like ABBV, VFF stock is not a pure marijuana play. AbbVie (NYSE:ABBV) GW Pharmaceuticals (NASDAQ:GWPH) Cresco Labs (OTCMKTS:CRLBF) GrowGeneration (NASDAQ:GRWG) Green Thumb Industries (OTCMKTS:GTBIF) Village Farms International (NASDAQ:VFF) Let’s take a closer look at wh... |
24,420 | 2020-08-20 00:00:00 UTC | Investing in These Stocks Now Could Make You a Millionaire Retiree | ABBV | https://www.nasdaq.com/articles/investing-in-these-stocks-now-could-make-you-a-millionaire-retiree-2020-08-20 | null | null | We all would like to be millionaires by the time we retire. With Social Security income likely to provide only a modest fraction of the income we need, most of us will have to come up with the rest of our needed cash flows on our own.
Fortunately, if you invest regularly and effectively for a long time, you can achieve... | Selena Maranjian owns shares of AbbVie, Amazon, Apple, AT&T, Microsoft, Netflix, Procter & Gamble, and Verizon Communications. 6.9% Chevron 5.7% AbbVie 5% MetLife 4.7% Duke Energy 4.7% Walgreens Boots Alliance 4.5% Verizon Communications 4.2% Citigroup 3.9% Boring stocks You might assume that you'll need to get lucky a... | 6.9% Chevron 5.7% AbbVie 5% MetLife 4.7% Duke Energy 4.7% Walgreens Boots Alliance 4.5% Verizon Communications 4.2% Citigroup 3.9% Selena Maranjian owns shares of AbbVie, Amazon, Apple, AT&T, Microsoft, Netflix, Procter & Gamble, and Verizon Communications. Sherwin-Williams 20% United Pacific 17.8% Nike 17% Public Stor... | 6.9% Chevron 5.7% AbbVie 5% MetLife 4.7% Duke Energy 4.7% Walgreens Boots Alliance 4.5% Verizon Communications 4.2% Citigroup 3.9% Selena Maranjian owns shares of AbbVie, Amazon, Apple, AT&T, Microsoft, Netflix, Procter & Gamble, and Verizon Communications. 5 years $63,359 $95,039 $126,718 10 years $156,455 $234,683 $3... | 6.9% Chevron 5.7% AbbVie 5% MetLife 4.7% Duke Energy 4.7% Walgreens Boots Alliance 4.5% Verizon Communications 4.2% Citigroup 3.9% Selena Maranjian owns shares of AbbVie, Amazon, Apple, AT&T, Microsoft, Netflix, Procter & Gamble, and Verizon Communications. We all would like to be millionaires by the time we retire. |
24,421 | 2020-08-19 00:00:00 UTC | FDA Denies Approval for Gilead Sciences' Potential Blockbuster Arthritis Drug | ABBV | https://www.nasdaq.com/articles/fda-denies-approval-for-gilead-sciences-potential-blockbuster-arthritis-drug-2020-08-19 | null | null | The space for oral rheumatoid arthritis treatments won't be getting crowded quite as quickly as some might have been expecting. Gilead Sciences (NASDAQ: GILD) told investors on Tuesday that the FDA has issued a complete response letter (CRL) denying approval for its drug candidate filgotinib -- for now -- and dealing a... | This setback for Gilead's drug will give recently launched oral rheumatoid arthritis (RA) treatments from AbbVie (NYSE: ABBV) and Eli Lily (NYSE: LLY) more time to establish their footholds in the highly lucrative market for immune system suppressants that safely prevent the disease from progressing. AbbVie's injectabl... | This setback for Gilead's drug will give recently launched oral rheumatoid arthritis (RA) treatments from AbbVie (NYSE: ABBV) and Eli Lily (NYSE: LLY) more time to establish their footholds in the highly lucrative market for immune system suppressants that safely prevent the disease from progressing. In 2019, AbbVie la... | This setback for Gilead's drug will give recently launched oral rheumatoid arthritis (RA) treatments from AbbVie (NYSE: ABBV) and Eli Lily (NYSE: LLY) more time to establish their footholds in the highly lucrative market for immune system suppressants that safely prevent the disease from progressing. AbbVie's injectabl... | AbbVie's injectable RA treatment, Humira is the world's top-selling drug; its annual sales peaked at $19.9 billion in 2018. In 2019, AbbVie launched Rinvoq, an oral RA treatment similar to filgotinib that generated an annualized $596 million during the second quarter. This setback for Gilead's drug will give recently l... |
24,422 | 2020-08-19 00:00:00 UTC | Validea John Neff Strategy Daily Upgrade Report - 8/19/2020 | ABBV | https://www.nasdaq.com/articles/validea-john-neff-strategy-daily-upgrade-report-8-19-2020-2020-08-19 | null | null | The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
LEIDOS HOLDINGS INC (LDOS) is a large-cap growth stock in the ... | Detailed Analysis of LEIDOS HOLDINGS INC Full Guru Analysis for LDOS Full Factor Report for LDOS ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysi... | Detailed Analysis of LEIDOS HOLDINGS INC Full Guru Analysis for LDOS Full Factor Report for LDOS ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysi... | Detailed Analysis of LEIDOS HOLDINGS INC Full Guru Analysis for LDOS Full Factor Report for LDOS ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysi... | Detailed Analysis of LEIDOS HOLDINGS INC Full Guru Analysis for LDOS Full Factor Report for LDOS ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysi... |
24,423 | 2020-08-18 00:00:00 UTC | New York charges Teva, Allergan with insurance fraud over opioid claims | ABBV | https://www.nasdaq.com/articles/new-york-charges-teva-allergan-with-insurance-fraud-over-opioid-claims-2020-08-18 | null | null | By Jonathan Stempel and Mrinalika Roy
NEW YORK, Aug 18 (Reuters) - New York state filed civil charges on Tuesday accusing Teva Pharmaceutical Industries Ltd TEVA.TA and Allergan Plc with insurance fraud for downplaying the risks of their opioid painkillers to patients and doctors.
Governor Andrew Cuomo said the charges... | Abbvie Inc ABBV.N, which bought Allergan in May, did not immediately respond to requests for comment. New York also accused Teva and Allergan of using "front groups" and doctors known as "key opinion leaders" to mislead people about the safety and effectiveness of opioids. Cuomo called the nation's opioid crisis "an Am... | Abbvie Inc ABBV.N, which bought Allergan in May, did not immediately respond to requests for comment. By Jonathan Stempel and Mrinalika Roy NEW YORK, Aug 18 (Reuters) - New York state filed civil charges on Tuesday accusing Teva Pharmaceutical Industries Ltd TEVA.TA and Allergan Plc with insurance fraud for downplaying... | Abbvie Inc ABBV.N, which bought Allergan in May, did not immediately respond to requests for comment. By Jonathan Stempel and Mrinalika Roy NEW YORK, Aug 18 (Reuters) - New York state filed civil charges on Tuesday accusing Teva Pharmaceutical Industries Ltd TEVA.TA and Allergan Plc with insurance fraud for downplaying... | Abbvie Inc ABBV.N, which bought Allergan in May, did not immediately respond to requests for comment. By Jonathan Stempel and Mrinalika Roy NEW YORK, Aug 18 (Reuters) - New York state filed civil charges on Tuesday accusing Teva Pharmaceutical Industries Ltd TEVA.TA and Allergan Plc with insurance fraud for downplaying... |
24,424 | 2020-08-18 00:00:00 UTC | ANALYSIS-U.S. activists complain that virtual shareholder meetings let companies silence them | ABBV | https://www.nasdaq.com/articles/analysis-u.s.-activists-complain-that-virtual-shareholder-meetings-let-companies-silence | null | null | By Jessica DiNapoli and Ross Kerber
NEW YORK/BOSTON, Aug 18 (Reuters) - Justin Danhof has used annual shareholder meetings to question companies on social issues for the last nine years.
His conservative think tank, the National Center for Public Policy Research, owns just a few shares in each of about 150 companies an... | Questions avoided this year ranged from online auctioneer eBay Inc EBAY.O declining to name directors who did not attend its online meeting to drug maker AbbVie Inc ABBV.N avoiding an inquiry on whether it would raise the cost of drugs during the pandemic. "As long-term investors, we were disappointed our question wasn... | Questions avoided this year ranged from online auctioneer eBay Inc EBAY.O declining to name directors who did not attend its online meeting to drug maker AbbVie Inc ABBV.N avoiding an inquiry on whether it would raise the cost of drugs during the pandemic. "As long-term investors, we were disappointed our question wasn... | Questions avoided this year ranged from online auctioneer eBay Inc EBAY.O declining to name directors who did not attend its online meeting to drug maker AbbVie Inc ABBV.N avoiding an inquiry on whether it would raise the cost of drugs during the pandemic. "As long-term investors, we were disappointed our question wasn... | Questions avoided this year ranged from online auctioneer eBay Inc EBAY.O declining to name directors who did not attend its online meeting to drug maker AbbVie Inc ABBV.N avoiding an inquiry on whether it would raise the cost of drugs during the pandemic. "As long-term investors, we were disappointed our question wasn... |
24,425 | 2020-08-16 00:00:00 UTC | Pfizer's Unheralded Franchise That's Worth Billions of Dollars | ABBV | https://www.nasdaq.com/articles/pfizers-unheralded-franchise-thats-worth-billions-of-dollars-2020-08-16 | null | null | Which of Pfizer's (NYSE: PFE) products grab investors' attention the most? I'd put BNT162b2, the COVID-19 vaccine candidate that Pfizer is developing with BioNTech, high on the list. The company's top-selling drugs Ibrance and Eliquis would also certainly make the cut. Pneumococcal vaccine Prevnar 13 might be worthy of... | In addition, Pfizer won FDA approval in November 2019 for Abrilada, a biosimilar to AbbVie's autoimmune-disease drug Humira. AbbVie built up a strong set of patents that protect its top-selling drug for a few more years. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights owns shares of AbbVie ... | In addition, Pfizer won FDA approval in November 2019 for Abrilada, a biosimilar to AbbVie's autoimmune-disease drug Humira. AbbVie built up a strong set of patents that protect its top-selling drug for a few more years. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights owns shares of AbbVie ... | In addition, Pfizer won FDA approval in November 2019 for Abrilada, a biosimilar to AbbVie's autoimmune-disease drug Humira. AbbVie built up a strong set of patents that protect its top-selling drug for a few more years. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights owns shares of AbbVie ... | In addition, Pfizer won FDA approval in November 2019 for Abrilada, a biosimilar to AbbVie's autoimmune-disease drug Humira. AbbVie built up a strong set of patents that protect its top-selling drug for a few more years. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights owns shares of AbbVie ... |
24,426 | 2020-08-16 00:00:00 UTC | 3 Dividend Stocks Yielding More Than 4% That Are Safe Buys Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-yielding-more-than-4-that-are-safe-buys-right-now-2020-08-16 | null | null | If you're retired (or close to that point), there are typically two main things you'll look for in stocks. First, the stock should pay an attractive dividend. Second, the underlying business should be solid and reliable.
Once you find stocks that check off these boxes, you can buy and hold without losing any sleep at ... | AbbVie AbbVie (NYSE: ABBV) pays the most attractive dividend of the three, with a juicy yield of close to 5%. Is that something for dividend investors to worry about, considering that Humira generated nearly 58% of AbbVie's total revenue last year? For one thing, Humira is now a smaller (although still important) part ... | AbbVie AbbVie (NYSE: ABBV) pays the most attractive dividend of the three, with a juicy yield of close to 5%. Is that something for dividend investors to worry about, considering that Humira generated nearly 58% of AbbVie's total revenue last year? For one thing, Humira is now a smaller (although still important) part ... | See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights owns shares of AbbVie and Brookfield Infrastructure Partners. AbbVie AbbVie (NYSE: ABBV) pays the most attractive dividend of the three, with a juicy yield of close to 5%. Is that something for dividend investors to worry about, considering th... | Is that something for dividend investors to worry about, considering that Humira generated nearly 58% of AbbVie's total revenue last year? * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie AbbVie (NYSE: ABBV) pays the most att... |
24,427 | 2020-08-13 00:00:00 UTC | Peek Under The Hood: SPYD Has 11% Upside | ABBV | https://www.nasdaq.com/articles/peek-under-the-hood%3A-spyd-has-11-upside-2020-08-13 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— Portfolio S&P 500— High D... | Although ABBV has traded at a recent price of $95.51/share, the average analyst target is 12.38% higher at $107.33/share. SPDR— Portfolio S&P 500— High Dividend ETF SPYD $29.31 $32.41 10.59% AbbVie Inc ABBV $95.51 $107.33 12.38% Philip Morris International Inc PM $79.69 $88.73 11.34% Altria Group Inc MO $42.96 $47.67 1... | Three of SPYD's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Philip Morris International Inc (Symbol: PM), and Altria Group Inc (Symbol: MO). SPDR— Portfolio S&P 500— High Dividend ETF SPYD $29.31 $32.41 10.59% AbbVie Inc ABBV $95.51 $107.33 12.38% Philip Morris ... | Three of SPYD's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Philip Morris International Inc (Symbol: PM), and Altria Group Inc (Symbol: MO). Although ABBV has traded at a recent price of $95.51/share, the average analyst target is 12.38% higher at $107.33/share.... | SPDR— Portfolio S&P 500— High Dividend ETF SPYD $29.31 $32.41 10.59% AbbVie Inc ABBV $95.51 $107.33 12.38% Philip Morris International Inc PM $79.69 $88.73 11.34% Altria Group Inc MO $42.96 $47.67 10.95% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months fro... |
24,428 | 2020-08-12 00:00:00 UTC | Notable Wednesday Option Activity: ABBV, GPRE, AMGN | ABBV | https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-abbv-gpre-amgn-2020-08-12 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 29,353 contracts have traded so far, representing approximately 2.9 million underlying shares. That amounts to about 44.8% of ABBV's average daily trading volume over ... | Particularly high volume was seen for the $82.50 strike put option expiring September 18, 2020, with 1,125 contracts trading so far today, representing approximately 112,500 underlying shares of ABBV. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc... | Below is a chart showing ABBV's trailing twelve month trading history, with the $82.50 strike highlighted in orange: Green Plains Inc. (Symbol: GPRE) options are showing a volume of 2,402 contracts thus far today. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today ... | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 29,353 contracts have traded so far, representing approximately 2.9 million underlying shares. Particularly high volume was seen for the $82.50 strike put option expir... | Below is a chart showing AMGN's trailing twelve month trading history, with the $275 strike highlighted in orange: For the various different available expirations for ABBV options, GPRE options, or AMGN options, visit StockOptionsChannel.com. Among the underlying components of the Russell 3000 index, we saw noteworthy ... |
24,429 | 2020-08-11 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2020-08-11 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | AbbVie Inc (Symbol: ABBV) $92.38 $104.50 13.12% Cincinnati Financial Corp. (Symbol: CINF) $83.42 $92.00 10.29% Becton, Dickinson & Co (Symbol: BDX) $256.75 $280.62 9.30% Stanley Black & Decker Inc (Symbol: SWK) $159.97 $172.00 7.52% S&P Global Inc (Symbol: SPGI) $344.07 $367.38 6.77% The average 12-month analyst target... | AbbVie Inc (Symbol: ABBV) $92.38 $104.50 13.12% Cincinnati Financial Corp. (Symbol: CINF) $83.42 $92.00 10.29% Becton, Dickinson & Co (Symbol: BDX) $256.75 $280.62 9.30% Stanley Black & Decker Inc (Symbol: SWK) $159.97 $172.00 7.52% S&P Global Inc (Symbol: SPGI) $344.07 $367.38 6.77% The average 12-month analyst target... | AbbVie Inc (Symbol: ABBV) $92.38 $104.50 13.12% Cincinnati Financial Corp. (Symbol: CINF) $83.42 $92.00 10.29% Becton, Dickinson & Co (Symbol: BDX) $256.75 $280.62 9.30% Stanley Black & Decker Inc (Symbol: SWK) $159.97 $172.00 7.52% S&P Global Inc (Symbol: SPGI) $344.07 $367.38 6.77% The average 12-month analyst target... | AbbVie Inc (Symbol: ABBV) $92.38 $104.50 13.12% Cincinnati Financial Corp. (Symbol: CINF) $83.42 $92.00 10.29% Becton, Dickinson & Co (Symbol: BDX) $256.75 $280.62 9.30% Stanley Black & Decker Inc (Symbol: SWK) $159.97 $172.00 7.52% S&P Global Inc (Symbol: SPGI) $344.07 $367.38 6.77% The average 12-month analyst target... |
24,430 | 2020-08-08 00:00:00 UTC | 3 Big Pharma Stocks With Surprising Cannabis Connections | ABBV | https://www.nasdaq.com/articles/3-big-pharma-stocks-with-surprising-cannabis-connections-2020-08-08 | null | null | While smaller drugmakers such as GW Pharmaceuticals (NASDAQ: GWPH) and Corbus Pharmaceuticals (NASDAQ: CRBP) have plowed headlong into medical marijuana research, most of the largest pharmaceutical companies have stayed on the sidelines. Most -- but not all. A few of the top names in the sector have recognized the pote... | Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Teva Pharmaceutical (NYSE: TEVA) are huge pharmaceutical companies that are less likely to see that same type of explosive growth in share price, but all three are establishing, at a distance, connections to medical marijuana. AbbVie has been applying for cannabis... | Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Teva Pharmaceutical (NYSE: TEVA) are huge pharmaceutical companies that are less likely to see that same type of explosive growth in share price, but all three are establishing, at a distance, connections to medical marijuana. AbbVie has been applying for cannabis... | Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Teva Pharmaceutical (NYSE: TEVA) are huge pharmaceutical companies that are less likely to see that same type of explosive growth in share price, but all three are establishing, at a distance, connections to medical marijuana. AbbVie has been applying for cannabis... | While AbbVie, the ninth-largest pharmaceutical company in the world by revenue, doesn't currently have any cannabis-related drugs in its catalog, it has filed for at least 59 cannabis-related patents in the United States, more than any other company, according to a 2019 report. Johnson & Johnson (NYSE: JNJ), AbbVie (NY... |
24,431 | 2020-08-07 00:00:00 UTC | AbbVie a Top Ranked SAFE Dividend Stock With 5.1% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-a-top-ranked-safe-dividend-stock-with-5.1-yield-abbv-2020-08-07 | null | null | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.1% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report.
Accor... | Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying h... | AbbVie Inc (Symbol: ABBV) made the "Dividend Channel S.A.F.E. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.74% of the SPDR S&P Divi... | According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.74% of the SPDR S&P Dividend ETF (SDY), which holds $291,848,191 worth of ABBV shares. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E.... | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.74% of the SPDR S&P Dividend ETF (SDY), which holds $291,848,191 worth of ABBV shares.... |
24,432 | 2020-08-07 00:00:00 UTC | 2 Coronavirus Stocks Robinhood Investors Love. Should You? | ABBV | https://www.nasdaq.com/articles/2-coronavirus-stocks-robinhood-investors-love.-should-you-2020-08-07 | null | null | Robinhood Markets is a financial services company that owns the stock-trading app Robinhood, which is highly popular among millennials. The company has made a habit of maintaining an updated list of the 100 most popular stocks on its platform.
A peek at the stocks in the most recent ranking (as of this writing) reveals... | I think it's likely that this drug will be approved and will go on to become a key growth driver for the company, especially considering its edge over its competitors, including AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Remicade. A peek at the stocks in the most recent ranking (as of this writing... | I think it's likely that this drug will be approved and will go on to become a key growth driver for the company, especially considering its edge over its competitors, including AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Remicade. In particular, Gilead Sciences (NASDAQ: GILD) and Sorrento Therapeu... | I think it's likely that this drug will be approved and will go on to become a key growth driver for the company, especially considering its edge over its competitors, including AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Remicade. A peek at the stocks in the most recent ranking (as of this writing... | I think it's likely that this drug will be approved and will go on to become a key growth driver for the company, especially considering its edge over its competitors, including AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Remicade. In particular, Gilead Sciences (NASDAQ: GILD) and Sorrento Therapeu... |
24,433 | 2020-08-06 00:00:00 UTC | AbbVie agrees to pay $24 mln to resolve Humira California lawsuit | ABBV | https://www.nasdaq.com/articles/abbvie-agrees-to-pay-%2424-mln-to-resolve-humira-california-lawsuit-2020-08-06-0 | null | null | Adds statement from AbbVie
Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday.
AbbVie denied the allegations, but agreed to look into how Humira is... | Insurance Commissioner Ricardo Lara said AbbVie has paid $24 million to California and the whistleblower, a registered nurse who brought the case to the department's attention in October 2016. AbbVie said in a statement it was glad the settlement allows its nurse ambassador program to continue with no significant chang... | Adds statement from AbbVie Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday. Insurance Commissioner Ricardo Lara said AbbVie has paid $24 million... | Adds statement from AbbVie Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday. AbbVie denied the allegations, but agreed to look into how Humira is... | AbbVie denied the allegations, but agreed to look into how Humira is marketed to health care providers in the state, the regulator said The Insurance Commissioner of California said the company also agreed to disclose that AbbVie, and not a medical provider, paid the registered nurses who are employed as so-called AbbV... |
24,434 | 2020-08-06 00:00:00 UTC | AbbVie agrees to pay $24 mln to resolve Humira California lawsuit | ABBV | https://www.nasdaq.com/articles/abbvie-agrees-to-pay-%2424-mln-to-resolve-humira-california-lawsuit-2020-08-06 | null | null | Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday.
AbbVie denied the allegations, but agreed to look into how Humira is marketed to health care pr... | Insurance Commissioner Ricardo Lara said AbbVie has paid $24 million to California and the whistleblower, a registered nurse who brought the case to the department's attention in October 2016. Among other things, the department alleged AbbVie violated California's Insurance Frauds Prevention Act by unlawfully providing... | Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday. Insurance Commissioner Ricardo Lara said AbbVie has paid $24 million to California and the whis... | Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday. AbbVie denied the allegations, but agreed to look into how Humira is marketed to health care pr... | AbbVie denied the allegations, but agreed to look into how Humira is marketed to health care providers in the state, the regulator said The Insurance Commissioner of California said the company also agreed to disclose that AbbVie, and not a medical provider, paid the registered nurses who are employed as so-called AbbV... |
24,435 | 2020-08-06 00:00:00 UTC | ABBV Named A Top Socially Responsible Dividend Stock | ABBV | https://www.nasdaq.com/articles/abbv-named-a-top-socially-responsible-dividend-stock-2020-08-06 | null | null | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... |
24,436 | 2020-08-04 00:00:00 UTC | How Neurocrine Biosciences Crushed It in Q2 | ABBV | https://www.nasdaq.com/articles/how-neurocrine-biosciences-crushed-it-in-q2-2020-08-04 | null | null | Neurocrine Biosciences' (NASDAQ: NBIX) 30% plunge earlier this year during the coronavirus-fueled market meltdown is practically all but forgotten now. The stock was up around 15% as of the market close on Monday.
But Neurocrine's shares are now likely to go even higher. The biotech announced its second-quarter results... | Most of the increase stemmed from a $30 million milestone payment from AbbVie associated with FDA approval for Oriahnn (elagolix) in treating uterine fibroids. The company could also begin to see small initial royalties from AbbVie's sales of Oriahnn that grow over time. See the 10 stocks *Stock Advisor returns as of J... | Most of the increase stemmed from a $30 million milestone payment from AbbVie associated with FDA approval for Oriahnn (elagolix) in treating uterine fibroids. The company could also begin to see small initial royalties from AbbVie's sales of Oriahnn that grow over time. See the 10 stocks *Stock Advisor returns as of J... | Most of the increase stemmed from a $30 million milestone payment from AbbVie associated with FDA approval for Oriahnn (elagolix) in treating uterine fibroids. The company could also begin to see small initial royalties from AbbVie's sales of Oriahnn that grow over time. See the 10 stocks *Stock Advisor returns as of J... | Most of the increase stemmed from a $30 million milestone payment from AbbVie associated with FDA approval for Oriahnn (elagolix) in treating uterine fibroids. The company could also begin to see small initial royalties from AbbVie's sales of Oriahnn that grow over time. See the 10 stocks *Stock Advisor returns as of J... |
24,437 | 2020-08-03 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Dynatrace, Carnival Corp, Atossa Therapeutics | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-microsoft-dynatrace-carnival-corp-atossa-therapeutics-2020-08 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes rose on Monday as a rebound in multi-billion dollar deals, including Microsoft's pursuit of TikTok's U.S. operations, lifted sent... | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.9% ** Cardinal Health Inc , up 5.2% ** Mckesson Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.8% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 6.6% ** Carnival Corp , down 5.7% The... | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.9% ** Cardinal Health Inc , up 5.2% ** Mckesson Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.8% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 6.6% ** Carnival Corp , down 5.7% The... | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.9% ** Cardinal Health Inc , up 5.2% ** Mckesson Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.8% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 6.6% ** Carnival Corp , down 5.7% The... | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.9% ** Cardinal Health Inc , up 5.2% ** Mckesson Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.8% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 6.6% ** Carnival Corp , down 5.7% The... |
24,438 | 2020-08-03 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Zovio, Tyson Foods, Mack-Cali Realty, Xerox | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-zovio-tyson-foods-mack-cali-realty-xerox-2020-08-03 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes rose on Monday as a rebound in multi-billion dollar deals, including Microsoft's pursuit of TikTok's U.S. operations, lifted sent... | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.6% ** Jacobs Engineering Group Inc , up 6.5% ** Cardinal Health Inc , up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.2% ** Carnival Corp CCL.N, down 4.9% ** Norwegian Cruise Line Holdings Ltd ,... | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.6% ** Jacobs Engineering Group Inc , up 6.5% ** Cardinal Health Inc , up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.2% ** Carnival Corp CCL.N, down 4.9% ** Norwegian Cruise Line Holdings Ltd ,... | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.6% ** Jacobs Engineering Group Inc , up 6.5% ** Cardinal Health Inc , up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.2% ** Carnival Corp CCL.N, down 4.9% ** Norwegian Cruise Line Holdings Ltd ,... | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.6% ** Jacobs Engineering Group Inc , up 6.5% ** Cardinal Health Inc , up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.2% ** Carnival Corp CCL.N, down 4.9% ** Norwegian Cruise Line Holdings Ltd ,... |
24,439 | 2020-08-03 00:00:00 UTC | AbbVie, Amgen, Takeda Pharma Enroll First Patients In I-SPY COVID Trial | ABBV | https://www.nasdaq.com/articles/abbvie-amgen-takeda-pharma-enroll-first-patients-in-i-spy-covid-trial-2020-08-03 | null | null | (RTTNews) - AbbVie, Inc. (ABBV), Amgen Inc. (AMGN), and Takeda Pharmaceutical Co. Ltd. (TAK) said Monday that they have enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial.
The t... | (RTTNews) - AbbVie, Inc. (ABBV), Amgen Inc. (AMGN), and Takeda Pharmaceutical Co. Ltd. (TAK) said Monday that they have enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The t... | (RTTNews) - AbbVie, Inc. (ABBV), Amgen Inc. (AMGN), and Takeda Pharmaceutical Co. Ltd. (TAK) said Monday that they have enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The I... | (RTTNews) - AbbVie, Inc. (ABBV), Amgen Inc. (AMGN), and Takeda Pharmaceutical Co. Ltd. (TAK) said Monday that they have enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The I... | (RTTNews) - AbbVie, Inc. (ABBV), Amgen Inc. (AMGN), and Takeda Pharmaceutical Co. Ltd. (TAK) said Monday that they have enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The t... |
24,440 | 2020-08-03 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Jernigan Capital, Keurig Dr Pepper, Spirit AeroSystems, Tyme Tech | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-jernigan-capital-keurig-dr-pepper-spirit-aerosystems-tyme | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes opened higher on Monday as Microsoft's pursuit of TikTok's U.S. operations and a clutch of upbeat quarterly earnings reports lift... | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 23% ** Kansas City So , up 4% ** Microsoft Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Loews Corp , down 6.1% ** Carnival Corp , down 3.6% ** Royal Caribbean Cruises Ltd , down 3.2% The top three NYSE .PG.N perce... | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 23% ** Kansas City So , up 4% ** Microsoft Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Loews Corp , down 6.1% ** Carnival Corp , down 3.6% ** Royal Caribbean Cruises Ltd , down 3.2% The top three NYSE .PG.N perce... | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 23% ** Kansas City So , up 4% ** Microsoft Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Loews Corp , down 6.1% ** Carnival Corp , down 3.6% ** Royal Caribbean Cruises Ltd , down 3.2% The top three NYSE .PG.N perce... | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 23% ** Kansas City So , up 4% ** Microsoft Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Loews Corp , down 6.1% ** Carnival Corp , down 3.6% ** Royal Caribbean Cruises Ltd , down 3.2% The top three NYSE .PG.N perce... |
24,441 | 2020-08-03 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-ADT Inc, Marathon Petroleum, Eli Lilly, VistaGen Therapeutics | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-adt-inc-marathon-petroleum-eli-lilly-vistagen-therapeutics | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes were set to open higher on Monday as Microsoft's pursuit of TikTok's U.S. operations and a clutch of upbeat quarterly earnings re... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 73.6% ** Borr Drillng Ltd , up 30.9% ** Forum Energy Technologies Inc , up 29.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** LMP Capital & Income Fund , down 21.6% ** Mogu Inc , down 14.1% ** Cango Inc , down 12.8% The top three N... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 73.6% ** Borr Drillng Ltd , up 30.9% ** Forum Energy Technologies Inc , up 29.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** LMP Capital & Income Fund , down 21.6% ** Mogu Inc , down 14.1% ** Cango Inc , down 12.8% The top three N... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 73.6% ** Borr Drillng Ltd , up 30.9% ** Forum Energy Technologies Inc , up 29.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** LMP Capital & Income Fund , down 21.6% ** Mogu Inc , down 14.1% ** Cango Inc , down 12.8% The top three N... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 73.6% ** Borr Drillng Ltd , up 30.9% ** Forum Energy Technologies Inc , up 29.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** LMP Capital & Income Fund , down 21.6% ** Mogu Inc , down 14.1% ** Cango Inc , down 12.8% The top three N... |
24,442 | 2020-08-03 00:00:00 UTC | Rival drugmakers launch joint trial of medicines for COVID-19 | ABBV | https://www.nasdaq.com/articles/rival-drugmakers-launch-joint-trial-of-medicines-for-covid-19-2020-08-03 | null | null | By Deena Beasley
Aug 3 (Reuters) - Rival drugmakers AbbVie Inc ABBV.N, Amgen Inc AMGN.O and Takeda Pharmaceuticals Inc 4502.T on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavi... | By Deena Beasley Aug 3 (Reuters) - Rival drugmakers AbbVie Inc ABBV.N, Amgen Inc AMGN.O and Takeda Pharmaceuticals Inc 4502.T on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavi... | The first segment will test whether Amgen's psoriasis drug Otezla, Takeda's anti-inflammatory Firazyr and AbbVie's cenicriviroc, which has been tried in patients with HIV, will help with the overactive, and potentially damaging, immune response that sometimes happens in patients with severe COVID-19. By Deena Beasley A... | By Deena Beasley Aug 3 (Reuters) - Rival drugmakers AbbVie Inc ABBV.N, Amgen Inc AMGN.O and Takeda Pharmaceuticals Inc 4502.T on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavi... | The first segment will test whether Amgen's psoriasis drug Otezla, Takeda's anti-inflammatory Firazyr and AbbVie's cenicriviroc, which has been tried in patients with HIV, will help with the overactive, and potentially damaging, immune response that sometimes happens in patients with severe COVID-19. By Deena Beasley A... |
24,443 | 2020-08-03 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Varian Medical, Pinterest, Chevron, AbbVie | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-varian-medical-pinterest-chevron-abbvie-2020-08-03 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Futures linked to the S&P 500 and the Dow indexes were muted on Monday with lawmakers at an impasse about a coronavirus relief deal, while investors remaine... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 62.4% ** Borr Drillng Ltd , up 32.1% ** Forum Energy Technologies Inc , up 23.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Cango Inc , down 12.8% ** Marine Products Corp , down 10.4% ** Mogu Inc , down 10.8% The top three Nasdaq... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 62.4% ** Borr Drillng Ltd , up 32.1% ** Forum Energy Technologies Inc , up 23.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Cango Inc , down 12.8% ** Marine Products Corp , down 10.4% ** Mogu Inc , down 10.8% The top three Nasdaq... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 62.4% ** Borr Drillng Ltd , up 32.1% ** Forum Energy Technologies Inc , up 23.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Cango Inc , down 12.8% ** Marine Products Corp , down 10.4% ** Mogu Inc , down 10.8% The top three Nasdaq... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 62.4% ** Borr Drillng Ltd , up 32.1% ** Forum Energy Technologies Inc , up 23.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Cango Inc , down 12.8% ** Marine Products Corp , down 10.4% ** Mogu Inc , down 10.8% The top three Nasdaq... |
24,444 | 2020-07-31 00:00:00 UTC | Drugmaker AbbVie profit beats as Humira helps offset COVID-19 hit | ABBV | https://www.nasdaq.com/articles/drugmaker-abbvie-profit-beats-as-humira-helps-offset-covid-19-hit-2020-07-31 | null | null | Adds CEO comment, shares
July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N on Friday reported a better-than-expected adjusted quarterly profit as sales of its blockbuster drug, Humira, more than offset weak demand for newly acquired aesthetic portfolio.
Share of the company were up 2.5% before the bell.
The company has l... | Adds CEO comment, shares July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N on Friday reported a better-than-expected adjusted quarterly profit as sales of its blockbuster drug, Humira, more than offset weak demand for newly acquired aesthetic portfolio. "The adverse impact from COVID-19 on legacy AbbVie was less than exp... | Adds CEO comment, shares July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N on Friday reported a better-than-expected adjusted quarterly profit as sales of its blockbuster drug, Humira, more than offset weak demand for newly acquired aesthetic portfolio. Excluding items, AbbVie reported a profit of $2.34 per share, beatin... | Adds CEO comment, shares July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N on Friday reported a better-than-expected adjusted quarterly profit as sales of its blockbuster drug, Humira, more than offset weak demand for newly acquired aesthetic portfolio. AbbVie said U.S. sales of Humira rose 4.8% to $3.97 billion, while i... | AbbVie said U.S. sales of Humira rose 4.8% to $3.97 billion, while international sales fell about 20% due to competition from cheaper versions. AbbVie forecast a combined company 2020 adjusted earnings estimate, which includes the results of Allergan from May 8 through Dec. 31, of $10.35 to $10.45 per share, representi... |
24,445 | 2020-07-31 00:00:00 UTC | Noteworthy Friday Option Activity: IBM, ABBV, F | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-ibm-abbv-f-2020-07-31 | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in International Business Machines Corp (Symbol: IBM), where a total volume of 22,995 contracts has been traded thus far today, a contract volume which is representative of approximately 2.3 million underlying ... | Especially high volume was seen for the $100 strike call option expiring September 18, 2020, with 2,760 contracts trading so far today, representing approximately 276,000 underlying shares of ABBV. Below is a chart showing IBM's trailing twelve month trading history, with the $122 strike highlighted in orange: AbbVie I... | Below is a chart showing IBM's trailing twelve month trading history, with the $122 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 26,481 contracts thus far today. Below is a chart showing ABBV's trailing twelve month trading history, with the $100 strike highlighted in orange: ... | Below is a chart showing ABBV's trailing twelve month trading history, with the $100 strike highlighted in orange: And Ford Motor Co. (Symbol: F) saw options trading volume of 313,567 contracts, representing approximately 31.4 million underlying shares or approximately 42.9% of F's average daily trading volume over the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $100 strike highlighted in orange: And Ford Motor Co. (Symbol: F) saw options trading volume of 313,567 contracts, representing approximately 31.4 million underlying shares or approximately 42.9% of F's average daily trading volume over the... |
24,446 | 2020-07-31 00:00:00 UTC | Validea Peter Lynch Strategy Daily Upgrade Report - 7/31/2020 | ABBV | https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-7-31-2020-2020-07-31 | null | null | The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology ... | ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV NORTHEAST BANK (NBN) is a small-cap value stock in the Reg... | Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV NORTHEAST BANK (NBN) is a small-cap value stock in the Regional Banks industry. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based bioph... | Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV NORTHEAST BANK (NBN) is a small-cap value stock in the Regional Banks industry. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based bioph... | ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV NORTHEAST BANK (NBN) is a small-cap value stock in the Reg... |
24,447 | 2020-07-31 00:00:00 UTC | After Hours Most Active for Jul 31, 2020 : CTL, RUN, AGNC, IAA, MSFT, FE, REXR, HPE, ABBV, QQQ, HBAN, NWL | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-for-jul-31-2020-%3A-ctl-run-agnc-iaa-msft-fe-rexr-hpe-abbv-qqq-hban | null | null | The NASDAQ 100 After Hours Indicator is up 2.51 to 10,908.39. The total After hours volume is currently 91,891,734 shares traded.
The following are the most active stocks for the after hours session:
CenturyLink, Inc. (CTL) is +0.04 at $9.69, with 5,843,336 shares traded.CTL is scheduled to provide an earnings report... | AbbVie Inc. (ABBV) is unchanged at $94.91, with 3,457,871 shares traded. PR Newswire Reports: AbbVie Reports Second-Quarter 2020 Financial Results CenturyLink, Inc. (CTL) is +0.04 at $9.69, with 5,843,336 shares traded.CTL is scheduled to provide an earnings report on 8/5/2020, for the fiscal quarter ending Jun2020. | AbbVie Inc. (ABBV) is unchanged at $94.91, with 3,457,871 shares traded. PR Newswire Reports: AbbVie Reports Second-Quarter 2020 Financial Results The consensus earnings per share forecast is 0.32 per share, which represents a 34 percent increase over the EPS one Year Ago | AbbVie Inc. (ABBV) is unchanged at $94.91, with 3,457,871 shares traded. PR Newswire Reports: AbbVie Reports Second-Quarter 2020 Financial Results The consensus earnings per share forecast is 0.32 per share, which represents a 34 percent increase over the EPS one Year Ago | AbbVie Inc. (ABBV) is unchanged at $94.91, with 3,457,871 shares traded. PR Newswire Reports: AbbVie Reports Second-Quarter 2020 Financial Results Over the last four weeks they have had 9 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2020. |
24,448 | 2020-07-31 00:00:00 UTC | 5 Key Things You'll Want to Know About AbbVie's Q2 Update | ABBV | https://www.nasdaq.com/articles/5-key-things-youll-want-to-know-about-abbvies-q2-update-2020-07-31 | null | null | AbbVie (NYSE: ABBV) announced its second-quarter results before the market opened on Friday. This quarterly update was significantly different than any other in the big drugmaker's history. That's because Q2 was the first time for AbbVie to report quarterly results after the closing of its acquisition of Allergan on Ma... | On an operational basis (calculated by assuming the Allergan acquisition occurred on Jan. 1, 2019), AbbVie's total revenue declined 5.3%. What to expect with the rest of the year AbbVie previously projected that its diluted EPS based on generally accepted accounting principles (GAAP) for full-year 2020 would be between... | Allergan acquisition hurt instead of helped AbbVie reported total revenue of $10.425 billion in Q2, up 26.3% year over year. Cancer drugs and new immunology drugs shined Now for some good news: AbbVie's cancer drugs and new immunology drugs performed very well in the second quarter. Even though AbbVie's revenue fell ye... | Allergan acquisition hurt instead of helped AbbVie reported total revenue of $10.425 billion in Q2, up 26.3% year over year. AbbVie reported sales of Humira totaled $4.84 billion in the second quarter, down 0.7% year over year. Cancer drugs and new immunology drugs shined Now for some good news: AbbVie's cancer drugs a... | That's because Q2 was the first time for AbbVie to report quarterly results after the closing of its acquisition of Allergan on May 8, 2020. How did AbbVie fare in its first quarterly results with Allergan under its wing? AbbVie reported sales of Humira totaled $4.84 billion in the second quarter, down 0.7% year over y... |
24,449 | 2020-07-31 00:00:00 UTC | AbbVie Q2 adjusted earnings Beat Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q2-adjusted-earnings-beat-estimates-2020-07-31 | null | null | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV):
-Earnings: -$738 million in Q2 vs. $741 million in the same period last year. -EPS: -$0.46 in Q2 vs. $0.49 in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.90 billion or $2.34 per share for the period. -Analysts proj... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: -$738 million in Q2 vs. $741 million in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.90 billion or $2.34 per share for the period. -Guidance: Full year EPS guidance: $10.35 to $10.45 The views and opinion... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: -$738 million in Q2 vs. $741 million in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.90 billion or $2.34 per share for the period. -Analysts projected $2.19 per share -Revenue: $10.43 billion in Q2 vs. $8... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: -$738 million in Q2 vs. $741 million in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.90 billion or $2.34 per share for the period. -Analysts projected $2.19 per share -Revenue: $10.43 billion in Q2 vs. $8... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: -$738 million in Q2 vs. $741 million in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.90 billion or $2.34 per share for the period. -Guidance: Full year EPS guidance: $10.35 to $10.45 The views and opinion... |
24,450 | 2020-07-31 00:00:00 UTC | AbbVie reports loss as COVID-19 hits Botox sales | ABBV | https://www.nasdaq.com/articles/abbvie-reports-loss-as-covid-19-hits-botox-sales-2020-07-31 | null | null | July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N reported a loss in the second quarter on Friday, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion Allergan Plc AGN.N deal, slumped due to the impact of the COVID-19 pandemic.
The company had cautioned earlier against a potential hit to... | July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N reported a loss in the second quarter on Friday, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion Allergan Plc AGN.N deal, slumped due to the impact of the COVID-19 pandemic. The drugmaker bought Allergan in May for a hefty sum, acquir... | July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N reported a loss in the second quarter on Friday, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion Allergan Plc AGN.N deal, slumped due to the impact of the COVID-19 pandemic. The drugmaker bought Allergan in May for a hefty sum, acquir... | July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N reported a loss in the second quarter on Friday, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion Allergan Plc AGN.N deal, slumped due to the impact of the COVID-19 pandemic. The drugmaker bought Allergan in May for a hefty sum, acquir... | The drugmaker bought Allergan in May for a hefty sum, acquiring its medical aesthetics business including Botox, hoping the segments would emerge as new growth drivers before AbbVie's arthritis drug, Humira, loses U.S. patent in 2023. July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N reported a loss in the second quarter... |
24,451 | 2020-07-31 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-AbbVie, Xilinx, Pinterest, Expedia Group | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-abbvie-xilinx-pinterest-expedia-group-2020-07-31 | null | null | * Eikon search string for individual stock moves: [STXBZ]
* The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
* The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped at the open on Friday, with Apple and Facebook hitting a record high as stunning quarterly reports from some of th... | The top three S&P 500 percentage gainers: ** Facebook Inc , up 7.6% ** Johnson Controls International PLC , up 5.5% ** Apple Inc , up 5.2% The top three S&P 500 percentage losers: ** Expedia Group Inc , down 6% ** Host Hotels & Resorts Inc , down 4.8% ** Alphabet Inc , down 4.4% The top three NYSE percentage gainers: *... | The top three S&P 500 percentage gainers: ** Facebook Inc , up 7.6% ** Johnson Controls International PLC , up 5.5% ** Apple Inc , up 5.2% The top three S&P 500 percentage losers: ** Expedia Group Inc , down 6% ** Host Hotels & Resorts Inc , down 4.8% ** Alphabet Inc , down 4.4% The top three NYSE percentage gainers: *... | The top three S&P 500 percentage gainers: ** Facebook Inc , up 7.6% ** Johnson Controls International PLC , up 5.5% ** Apple Inc , up 5.2% The top three S&P 500 percentage losers: ** Expedia Group Inc , down 6% ** Host Hotels & Resorts Inc , down 4.8% ** Alphabet Inc , down 4.4% The top three NYSE percentage gainers: *... | The top three S&P 500 percentage gainers: ** Facebook Inc , up 7.6% ** Johnson Controls International PLC , up 5.5% ** Apple Inc , up 5.2% The top three S&P 500 percentage losers: ** Expedia Group Inc , down 6% ** Host Hotels & Resorts Inc , down 4.8% ** Alphabet Inc , down 4.4% The top three NYSE percentage gainers: *... |
24,452 | 2020-07-31 00:00:00 UTC | AbbVie (ABBV) Q2 2020 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q2-2020-earnings-call-transcript-2020-08-01 | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q2 2020 Earnings Call
Jul 31, 2020, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, and thank you for standing by. Welcome to the AbbVie second-quarter 2020earnings conference call [Operator inst... | With the closing of the Allergan transaction, AbbVie is well positioned for enhanced long-term growth potential, a growing dividend, rapid debt repayment and strong investment in innovation across our therapeutic categories. AbbVie remains well positioned to execute on our capital allocation priorities including rapidl... | Operator [Operator signoff] Duration: 83 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Michael Severino -- Vice Chairman and President Rob Michael -- Executive Vice President and Chief Financial Officer Randall Stanicky -- ... | Total revenues were $10.4 billion including approximately $8.4 billion of legacy AbbVie sales, significantly above our expectations for the stand-alone portfolio, with continued robust performance in both hem/onc and immunology despite the impact from COVID. Operator [Operator signoff] Duration: 83 minutes Call partici... | Operator [Operator signoff] Duration: 83 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Michael Severino -- Vice Chairman and President Rob Michael -- Executive Vice President and Chief Financial Officer Randall Stanicky -- ... |
24,453 | 2020-07-30 00:00:00 UTC | Pre-Market Earnings Report for July 31, 2020 : MRK, XOM, CVX, ABBV, CHTR, CAT, D, CL, ITW, AON, LHX, IDXX | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-july-31-2020-%3A-mrk-xom-cvx-abbv-chtr-cat-d-cl-itw-aon-lhx | null | null | The following companies are expected to report earnings prior to market open on 07/31/2020. Visit our Earnings Calendar for a full list of expected earnings releases.
Merck & Company, Inc. (MRK) is reporting for the quarter ending June 30, 2020. The large cap pharmaceutical company's consensus earnings per share forec... | AbbVie Inc. (ABBV) is reporting for the quarter ending June 30, 2020. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.28 vs. an industry ratio of 16.40. | AbbVie Inc. (ABBV) is reporting for the quarter ending June 30, 2020. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.28 vs. an industry ratio of 16.40. | AbbVie Inc. (ABBV) is reporting for the quarter ending June 30, 2020. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.28 vs. an industry ratio of 16.40. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. (ABBV) is reporting for the quarter ending June 30, 2020. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.28 vs. an industry ratio of 16.40. |
24,454 | 2020-07-29 00:00:00 UTC | Why Alector Is Tumbling 28.7% Today | ABBV | https://www.nasdaq.com/articles/why-alector-is-tumbling-28.7-today-2020-07-29 | null | null | What happened
Shares in Alector (NASDAQ: ALEC) are tumbling 28.7% at 12:30 p.m. EDT on Wednesday over concerns COVID-19 could negatively impact patient enrollment and monitoring in clinical-stage trials of AL001.
So what
The biotech company's AL001 is being evaluated for use in frontotemporal dementia patients with a p... | Nevertheless, Alector had $548 million in cash on its balance sheet as of March 31, and it has multiple intriguing drugs in development, including AL002, an Alzheimer's disease drug licensed to AbbVie that's expected to enter phase 2 trials this year. What happened Shares in Alector (NASDAQ: ALEC) are tumbling 28.7% at... | Nevertheless, Alector had $548 million in cash on its balance sheet as of March 31, and it has multiple intriguing drugs in development, including AL002, an Alzheimer's disease drug licensed to AbbVie that's expected to enter phase 2 trials this year. As a result, some participants missed a dose of AL001 or missed clin... | Nevertheless, Alector had $548 million in cash on its balance sheet as of March 31, and it has multiple intriguing drugs in development, including AL002, an Alzheimer's disease drug licensed to AbbVie that's expected to enter phase 2 trials this year. Specifically, no treatment-related serious adverse events were obser... | Nevertheless, Alector had $548 million in cash on its balance sheet as of March 31, and it has multiple intriguing drugs in development, including AL002, an Alzheimer's disease drug licensed to AbbVie that's expected to enter phase 2 trials this year. Alector plans on enrolling 40 people in its phase 2 study, and a pha... |
24,455 | 2020-07-29 00:00:00 UTC | AbbVie Announces Positive Late-stage Data For Atogepant In Migraine Prevention | ABBV | https://www.nasdaq.com/articles/abbvie-announces-positive-late-stage-data-for-atogepant-in-migraine-prevention-2020-07-29 | null | null | (RTTNews) - AbbVie (ABBV) said that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide receptor antagonist or gepant met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to place... | (RTTNews) - AbbVie (ABBV) said that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide receptor antagonist or gepant met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to place... | (RTTNews) - AbbVie (ABBV) said that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide receptor antagonist or gepant met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to place... | (RTTNews) - AbbVie (ABBV) said that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide receptor antagonist or gepant met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to place... | (RTTNews) - AbbVie (ABBV) said that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide receptor antagonist or gepant met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to place... |
24,456 | 2020-07-26 00:00:00 UTC | 3 Coronavirus Stocks With the Highest Dividend Yields | ABBV | https://www.nasdaq.com/articles/3-coronavirus-stocks-with-the-highest-dividend-yields-2020-07-26 | null | null | Great growth prospects might be the first thing that comes to mind when you think about coronavirus stocks. And several companies with COVID-19 programs certainly do have strong growth opportunities.
On the other hand, it's likely that dividends wouldn't be the first thought on most investors' minds when the topic of c... | However, AbbVie is evaluating Imbruvica in a phase 2 study to see if its cancer drug can reduce severe immune responses known as cytokine storms in COVID-19 patients. AbbVie AbbVie (NYSE: ABBV) runs neck-and-neck with Takeda. In addition, AbbVie is a Dividend Aristocrat with 47 consecutive years of dividend increases. | AbbVie AbbVie (NYSE: ABBV) runs neck-and-neck with Takeda. In addition, AbbVie is a Dividend Aristocrat with 47 consecutive years of dividend increases. However, AbbVie is evaluating Imbruvica in a phase 2 study to see if its cancer drug can reduce severe immune responses known as cytokine storms in COVID-19 patients. | In addition, AbbVie is a Dividend Aristocrat with 47 consecutive years of dividend increases. AbbVie AbbVie (NYSE: ABBV) runs neck-and-neck with Takeda. However, AbbVie is evaluating Imbruvica in a phase 2 study to see if its cancer drug can reduce severe immune responses known as cytokine storms in COVID-19 patients. | AbbVie AbbVie (NYSE: ABBV) runs neck-and-neck with Takeda. In addition, AbbVie is a Dividend Aristocrat with 47 consecutive years of dividend increases. However, AbbVie is evaluating Imbruvica in a phase 2 study to see if its cancer drug can reduce severe immune responses known as cytokine storms in COVID-19 patients. |
24,457 | 2020-07-25 00:00:00 UTC | 2 Market-Beating Dividend Stocks With Above-Average Payouts | ABBV | https://www.nasdaq.com/articles/2-market-beating-dividend-stocks-with-above-average-payouts-2020-07-25 | null | null | It's been a volatile year in the markets, and the S&P 500's returns are flat year to date. While that's good news for investors who were fearing the worst (a prolonged market crash) in March, 2020's still been a lousy year for many stocks. But two stocks have been the exception to the norm, outperforming the markets an... | The drug added $300 million in revenue in Q1; in the same period a year ago, it wasn't yet contributing anything to AbbVie's top line. AbbVie, with its incorporation of Allergan, looks to be in a better position to generate more sustainable sales growth in future years now that it has a more diversified portfolio of dr... | AbbVie AbbVie (NYSE: ABBV) is an even stronger, more versatile healthcare stock to hold in your portfolio now that it's completed its $63 billion acquisition of Botox maker Allergan. AbbVie made the announcement on May 8 that the deal was final, calling it a "turning point" that will allow the now stronger biopharmaceu... | AbbVie AbbVie (NYSE: ABBV) is an even stronger, more versatile healthcare stock to hold in your portfolio now that it's completed its $63 billion acquisition of Botox maker Allergan. AbbVie made the announcement on May 8 that the deal was final, calling it a "turning point" that will allow the now stronger biopharmaceu... | AbbVie, with its incorporation of Allergan, looks to be in a better position to generate more sustainable sales growth in future years now that it has a more diversified portfolio of drugs to work with. AbbVie AbbVie (NYSE: ABBV) is an even stronger, more versatile healthcare stock to hold in your portfolio now that it... |
24,458 | 2020-07-24 00:00:00 UTC | ESGV, FB, ABBV, COST: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/esgv-fb-abbv-cost%3A-etf-inflow-alert-2020-07-24 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard ESG U.S. Stock ETF (Symbol: ESGV) where we have detected an approximate $109.1 million dollar inflow -- that's a 7.1% increase week over week in outstanding units (from 25,950,000 t... | Among the largest underlying components of ESGV, in trading today Facebook Inc (Symbol: FB) is off about 1.2%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.1%. For a complete list of holdings, visit the ESGV Holdings page » The chart below shows the one year... | Among the largest underlying components of ESGV, in trading today Facebook Inc (Symbol: FB) is off about 1.2%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... | Among the largest underlying components of ESGV, in trading today Facebook Inc (Symbol: FB) is off about 1.2%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... | Among the largest underlying components of ESGV, in trading today Facebook Inc (Symbol: FB) is off about 1.2%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... |
24,459 | 2020-07-24 00:00:00 UTC | 5 High-Yield Drug Stocks That Are Undervalued With Great Upside | ABBV | https://www.nasdaq.com/articles/5-high-yield-drug-stocks-that-are-undervalued-with-great-upside-2020-07-24 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
These five high yield drug stocks pay dividends with attractive yields, and also are undervalued. And as a result, these stocks offer good upside potential to investors. As a group, they are cheap. Yet, they have solid earnings that cover their dividends, p... | 10 Cybersecurity Stocks We Need Now More Than Ever That said, the five high yield drug stocks are: AbbVie (NYSE:ABBV) GlaxoSmithKline (NYSE:GSK) Novartis (NYSE:NVS) Pfizer (NYSE:PFE) Sanofi (NASDAQ:SNY) So, with all of that in mind, let’s dive in. High-Yield Drug Stocks: AbbVie (ABBV) Click to Enlarge Source: Mark R. H... | 10 Cybersecurity Stocks We Need Now More Than Ever That said, the five high yield drug stocks are: AbbVie (NYSE:ABBV) GlaxoSmithKline (NYSE:GSK) Novartis (NYSE:NVS) Pfizer (NYSE:PFE) Sanofi (NASDAQ:SNY) So, with all of that in mind, let’s dive in. Click to Enlarge Source: Mark R. Hake, CFA Market Value: $170 billion Fo... | Click to Enlarge Source: Mark R. Hake, CFA Market Value: $170 billion Forward P/E: 8.3x Dividend Yield: 4.8% Target Price Upside: 87% AbbVie stock is a large $170 billion market capitalization drug stock that is both cheap and has a very attractive dividend yield. 10 Cybersecurity Stocks We Need Now More Than Ever That... | Click to Enlarge Source: Mark R. Hake, CFA Market Value: $170 billion Forward P/E: 8.3x Dividend Yield: 4.8% Target Price Upside: 87% AbbVie stock is a large $170 billion market capitalization drug stock that is both cheap and has a very attractive dividend yield. 10 Cybersecurity Stocks We Need Now More Than Ever That... |
24,460 | 2020-07-23 00:00:00 UTC | The 8 Most Reliable Blue-Chip Stocks In the Market Today | ABBV | https://www.nasdaq.com/articles/the-8-most-reliable-blue-chip-stocks-in-the-market-today-2020-07-23 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Buying blue-chip stocks usually comes with the idea that you’re not really going to be wringing all the best out of growth in the markets.
You get big, diversified companies that are built for stability rather than speed.
But nothing can be further from the... | Amazon (NASDAQ:AMZN) Apple (NASDAQ:AAPL) Microsoft (NASDAQ:MSFT) Dollar General (NYSE:DG) AbbVie (NYSE:ABBV) Walmart (NYSE:WMT) Visa (NYSE:V) Procter & Gamble (NYSE:PG) Here’s a look at what makes each a dependable investment today. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source:... | Amazon (NASDAQ:AMZN) Apple (NASDAQ:AAPL) Microsoft (NASDAQ:MSFT) Dollar General (NYSE:DG) AbbVie (NYSE:ABBV) Walmart (NYSE:WMT) Visa (NYSE:V) Procter & Gamble (NYSE:PG) Here’s a look at what makes each a dependable investment today. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source:... | Amazon (NASDAQ:AMZN) Apple (NASDAQ:AAPL) Microsoft (NASDAQ:MSFT) Dollar General (NYSE:DG) AbbVie (NYSE:ABBV) Walmart (NYSE:WMT) Visa (NYSE:V) Procter & Gamble (NYSE:PG) Here’s a look at what makes each a dependable investment today. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source:... | Amazon (NASDAQ:AMZN) Apple (NASDAQ:AAPL) Microsoft (NASDAQ:MSFT) Dollar General (NYSE:DG) AbbVie (NYSE:ABBV) Walmart (NYSE:WMT) Visa (NYSE:V) Procter & Gamble (NYSE:PG) Here’s a look at what makes each a dependable investment today. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source:... |
24,461 | 2020-07-23 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Microsoft Corp, Tesla Inc | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-microsoft-corp-tesla-inc-2020-07-23 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
S&P 500 and Dow futures hovered near five-month highs on Thursday, as signs that a new coronavirus relief package was at hand lifted sentiment ahead of week... | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh S&P 500 and Dow futures hovered near five-month highs on Thursday, as signs that a new coronavirus relief package was at hand lifted sentiment ahead of week... | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh S&P 500 and Dow futures hovered near five-month highs on Thursday, as signs that a new coronavirus relief package was at hand lifted sentiment ahead of week... | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh S&P 500 and Dow futures hovered near five-month highs on Thursday, as signs that a new coronavirus relief package was at hand lifted sentiment ahead of week... | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh S&P 500 and Dow futures hovered near five-month highs on Thursday, as signs that a new coronavirus relief package was at hand lifted sentiment ahead of week... |
24,462 | 2020-07-22 00:00:00 UTC | Is AbbVie a Great Dividend Stock? | ABBV | https://www.nasdaq.com/articles/is-abbvie-a-great-dividend-stock-2020-07-22 | null | null | Many investors consider dividend stocks an important part of any well-rounded portfolio. And while there is no shortage of such stocks on the market, they aren't all created equal. After all, most companies aren't legally obligated to reward shareholders by way of dividends, and given that we are currently in a recessi... | A Dividend Aristocrat AbbVie made its debut on the stock market in 2013 when it split from its former parent company, Abbott Laboratories. The key takeaway It is worth noting that AbbVie's acquisition of Allergan significantly increased its debt level. However, AbbVie's CEO, Richard Gonzalez, had this to stay during th... | AbbVie can still deliver strong financial results Even though AbbVie boasts a stellar dividend history, a high dividend yield, and a reasonable payout ratio, it is critical to ensure that the company can continue growing its revenue and earnings at a good clip before adding it to your dividend portfolio. The key takeaw... | When we include the time AbbVie spent as a division of Abbott, the company has raised its dividends for 47 consecutive years, making the drugmaker a Dividend Aristocrat. AbbVie can still deliver strong financial results Even though AbbVie boasts a stellar dividend history, a high dividend yield, and a reasonable payout... | AbbVie can still deliver strong financial results Even though AbbVie boasts a stellar dividend history, a high dividend yield, and a reasonable payout ratio, it is critical to ensure that the company can continue growing its revenue and earnings at a good clip before adding it to your dividend portfolio. * David and To... |
24,463 | 2020-07-22 00:00:00 UTC | Validea John Neff Strategy Daily Upgrade Report - 7/22/2020 | ABBV | https://www.nasdaq.com/articles/validea-john-neff-strategy-daily-upgrade-report-7-22-2020-2020-07-22 | null | null | The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
UNITEDHEALTH GROUP INC (UNH) is a large-cap growth stock in th... | Detailed Analysis of GUARANTY BANCSHARES, INC. Full Guru Analysis for GNTY Full Factor Report for GNTY ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru A... | Detailed Analysis of GUARANTY BANCSHARES, INC. Full Guru Analysis for GNTY Full Factor Report for GNTY ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru A... | Detailed Analysis of GUARANTY BANCSHARES, INC. Full Guru Analysis for GNTY Full Factor Report for GNTY ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru A... | Detailed Analysis of GUARANTY BANCSHARES, INC. Full Guru Analysis for GNTY Full Factor Report for GNTY ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru A... |
24,464 | 2020-07-21 00:00:00 UTC | Gilead Sciences Invests $300 Million in an Immuno-Oncology Startup | ABBV | https://www.nasdaq.com/articles/gilead-sciences-invests-%24300-million-in-an-immuno-oncology-startup-2020-07-21 | null | null | Gilead Sciences (NASDAQ: GILD) announced Tuesday it's paying $300 million for a 49.9% ownership stake in Tizona Therapeutics and an option to acquire the company outright later for up to $1.25 billion in fees and potential milestone payments.
The deal provides the privately owned company with financing to support the d... | An anti-CD39 antibody, TTX-030 is being developed in partnership with AbbVie (NYSE: ABBV). Gilead Sciences (NASDAQ: GILD) announced Tuesday it's paying $300 million for a 49.9% ownership stake in Tizona Therapeutics and an option to acquire the company outright later for up to $1.25 billion in fees and potential milest... | An anti-CD39 antibody, TTX-030 is being developed in partnership with AbbVie (NYSE: ABBV). The deal provides the privately owned company with financing to support the development of TTX-080, a potential first-in-class immunotherapy targeting HLA-G, an immune checkpoint molecule expressed in multiple tumor types. If suc... | An anti-CD39 antibody, TTX-030 is being developed in partnership with AbbVie (NYSE: ABBV). Gilead Sciences (NASDAQ: GILD) announced Tuesday it's paying $300 million for a 49.9% ownership stake in Tizona Therapeutics and an option to acquire the company outright later for up to $1.25 billion in fees and potential milest... | An anti-CD39 antibody, TTX-030 is being developed in partnership with AbbVie (NYSE: ABBV). The deal provides the privately owned company with financing to support the development of TTX-080, a potential first-in-class immunotherapy targeting HLA-G, an immune checkpoint molecule expressed in multiple tumor types. The bi... |
24,465 | 2020-07-21 00:00:00 UTC | Gilead To Acquire 49.9% Equity Interest In Tizona - Quick Facts | ABBV | https://www.nasdaq.com/articles/gilead-to-acquire-49.9-equity-interest-in-tizona-quick-facts-2020-07-21 | null | null | (RTTNews) - Gilead Sciences, Inc. (GILD) said the company will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc., a privately held company developing cancer immunotherapies. The U.S. FDA has approved Tizona's Investigational New Drug application for TTX-080. Tizona plans to begi... | Tizona will spin off TTX-030, the company's investigational anti-CD39 antibody partnered with AbbVie, into a separate entity prior to closing of the deal. Tizona plans to begin a Phase 1 clinical trial evaluating TTX-080 both as a monotherapy and in combination with other agents in patients with advanced cancers. Tizon... | Tizona will spin off TTX-030, the company's investigational anti-CD39 antibody partnered with AbbVie, into a separate entity prior to closing of the deal. The U.S. FDA has approved Tizona's Investigational New Drug application for TTX-080. Gilead will have an exclusive option to purchase the remaining equity of Tizona ... | Tizona will spin off TTX-030, the company's investigational anti-CD39 antibody partnered with AbbVie, into a separate entity prior to closing of the deal. (RTTNews) - Gilead Sciences, Inc. (GILD) said the company will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc., a privatel... | Tizona will spin off TTX-030, the company's investigational anti-CD39 antibody partnered with AbbVie, into a separate entity prior to closing of the deal. (RTTNews) - Gilead Sciences, Inc. (GILD) said the company will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc., a privatel... |
24,466 | 2020-07-21 00:00:00 UTC | 2 High-Yield Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/2-high-yield-dividend-stocks-id-buy-right-now-2020-07-21 | null | null | When evaluating dividend-paying stocks, it's important to consider the company's overall business prospects and the dividend growth record. It's a lot more fun watching share price increases while accumulating growing dividend payouts than falling for unsustainably high dividend yields and watching your investment drop... | AbbVie's stock price has been held back due to future uncertainty about losing exclusivity on its blockbuster immunology drug Humira in 2023. That's why I like rock-solid companies like AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) for investors looking for dividends. Reasons to be in AbbVie: valuation and divi... | That's why I like rock-solid companies like AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) for investors looking for dividends. Reasons to be in AbbVie: valuation and dividend yield There's a lot to like about pharmaceutical firm AbbVie's 4.8% dividend. AbbVie's stock price has been held back due to future uncer... | That's why I like rock-solid companies like AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) for investors looking for dividends. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Anne Burdakin owns shares of AbbVie and Johnson & Johnson. Reasons to be in AbbVie: valuation and dividend yield There's a lo... | See the 10 stocks *Stock Advisor returns as of June 2, 2020 Anne Burdakin owns shares of AbbVie and Johnson & Johnson. That's why I like rock-solid companies like AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) for investors looking for dividends. Reasons to be in AbbVie: valuation and dividend yield There's a lo... |
24,467 | 2020-07-21 00:00:00 UTC | 2 Best Gene-Editing Stocks to Buy in July | ABBV | https://www.nasdaq.com/articles/2-best-gene-editing-stocks-to-buy-in-july-2020-07-21 | null | null | Gene-editing stocks are favorites for biotech industry speculators thanks to their air of high-tech mystique and their potential to make blockbuster therapies. According to Market Research Future, the global genome editing market will expand at a compound annual growth rate of 18.3% over the next three years. Many inve... | Growing revenues from these collaborations is one of the company's talents, with Abbvie retaining the option to license up to five new eye health programs and Bristol Myers Squibb paying $100 million up front for its immuno-oncology drug discovery contract. Like CRISPR, Editas has a roster of large collaborators includ... | Like CRISPR, Editas has a roster of large collaborators including Abbvie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Growing revenues from these collaborations is one of the company's talents, with Abbvie retaining the option to license up to five new eye health programs and Bristol Myers Squibb paying $100 mill... | Like CRISPR, Editas has a roster of large collaborators including Abbvie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Growing revenues from these collaborations is one of the company's talents, with Abbvie retaining the option to license up to five new eye health programs and Bristol Myers Squibb paying $100 mill... | Like CRISPR, Editas has a roster of large collaborators including Abbvie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Growing revenues from these collaborations is one of the company's talents, with Abbvie retaining the option to license up to five new eye health programs and Bristol Myers Squibb paying $100 mill... |
24,468 | 2020-07-19 00:00:00 UTC | 3 Fantastic Dividend Stocks to Buy When the Market Crashes Again | ABBV | https://www.nasdaq.com/articles/3-fantastic-dividend-stocks-to-buy-when-the-market-crashes-again-2020-07-19 | null | null | Yes, the stock market will crash again. That's a 100% certainty. What isn't so certain is when it will happen. But you can bet on another market crash coming down the road, perhaps even this year.
If you do take that bet, though, make sure you hold some cash to the side. Major market downturns create excellent buying o... | AbbVie At last, we have a great dividend stock to buy in the next market crash that isn't named Brookfield. AbbVie (NYSE: ABBV) offers a dividend yield of 4.7% -- the highest of the group. I'll admit that AbbVie might seem like somewhat riskier than the Brookfield companies. | See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. AbbVie At last, we have a great dividend stock to buy in the next market crash that isn't named Brookfield. AbbVie (NYSE... | AbbVie At last, we have a great dividend stock to buy in the next market crash that isn't named Brookfield. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. AbbVie (NYSE... | AbbVie At last, we have a great dividend stock to buy in the next market crash that isn't named Brookfield. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. AbbVie (NYSE... |
24,469 | 2020-07-17 00:00:00 UTC | South Korea approves human trials of Celltrion's COVID-19 antibody drug | ABBV | https://www.nasdaq.com/articles/south-korea-approves-human-trials-of-celltrions-covid-19-antibody-drug-2020-07-17 | null | null | By Sangmi Cha
SEOUL, July 17 (Reuters) - South Korea on Friday approved an early stage clinical trial of Celltrion Inc's 068270.KS experimental COVID-19 treatment drug, making it the country's first such antibody drug to be tested on humans.
Drugmakers worldwide are scrambling to develop vaccines and treatments for the... | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. Drugmakers worldwide are scrambling to develop vaccines and treatments for the flu-like illness caused by the novel coronavirus that has infected nearly 14 million people and ... | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. By Sangmi Cha SEOUL, July 17 (Reuters) - South Korea on Friday approved an early stage clinical trial of Celltrion Inc's 068270.KS experimental COVID-19 treatment drug, making... | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. By Sangmi Cha SEOUL, July 17 (Reuters) - South Korea on Friday approved an early stage clinical trial of Celltrion Inc's 068270.KS experimental COVID-19 treatment drug, making... | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. By Sangmi Cha SEOUL, July 17 (Reuters) - South Korea on Friday approved an early stage clinical trial of Celltrion Inc's 068270.KS experimental COVID-19 treatment drug, making... |
24,470 | 2020-07-17 00:00:00 UTC | These 3 Stocks Are Still Ridiculously Cheap Right Now | ABBV | https://www.nasdaq.com/articles/these-3-stocks-are-still-ridiculously-cheap-right-now-2020-07-17 | null | null | In some ways, the stock market crash earlier this year seems like a distant memory. After all, we just experienced one of the best quarterly stock market performances in decades in the Q2. Now, you're likely to hear people talk about how steep the market's valuation is.
But not every stock is priced at a premium. In fa... | AbbVie AbbVie (NYSE: ABBV) shares are up more than 20% in the last three months. There's one obvious reason why AbbVie sports such a cheap valuation. More importantly, AbbVie has other arrows in its quiver that will help offset future sales declines for Humira, notable among them new immunology drugs Rinvoq and Skyrizi... | AbbVie won't have to deliver impressive earnings growth to provide an attractive total return. AbbVie AbbVie (NYSE: ABBV) shares are up more than 20% in the last three months. There's one obvious reason why AbbVie sports such a cheap valuation. | See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie AbbVie (NYSE: ABBV) shares are up more than 20% in the last three months. There's one obvious reason why AbbVie sports such a cheap valuation. | See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie AbbVie (NYSE: ABBV) shares are up more than 20% in the last three months. There's one obvious reason why AbbVie sports such a cheap valuation. |
24,471 | 2020-07-16 00:00:00 UTC | iShares Russell Top 200 Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-top-200-growth-etf-experiences-big-inflow-2020-07-16 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Top 200 Growth ETF (Symbol: IWY) where we have detected an approximate $106.7 million dollar inflow -- that's a 4.0% increase week over week in outstanding units (from 24,050... | Among the largest underlying components of IWY, in trading today Facebook Inc (Symbol: FB) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is down about 1.4%, and ServiceNow Inc (Symbol: NOW) is lower by about 3%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price perfo... | Among the largest underlying components of IWY, in trading today Facebook Inc (Symbol: FB) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is down about 1.4%, and ServiceNow Inc (Symbol: NOW) is lower by about 3%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price perfo... | Among the largest underlying components of IWY, in trading today Facebook Inc (Symbol: FB) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is down about 1.4%, and ServiceNow Inc (Symbol: NOW) is lower by about 3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of IWY, in trading today Facebook Inc (Symbol: FB) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is down about 1.4%, and ServiceNow Inc (Symbol: NOW) is lower by about 3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... |
24,472 | 2020-07-14 00:00:00 UTC | The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase | ABBV | https://www.nasdaq.com/articles/the-7-best-pharmaceutical-stocks-that-go-beyond-the-covid-19-chase-2020-07-14 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It’s easy to miss the forest for the trees in markets like this. Especially when it comes to pharmaceutical stocks.
What I mean is that, in some sectors, there are great stocks that get overlooked because a few of them are working on event-driven issues, wh... | They are: United Therapeutics (NASDAQ:UTHR) Novo Nordisk (NYSE:NVO) Dr Reddy’s Laboratories (NYSE:RDY) AbbVie (NYSE:ABBV) Eli Lilly & Co (NYSE:LLY) Zoetis (NYSE:ZTS) Horizon Therapeutics (NASDAQ:HZNP) Let’s look at what makes each worth your consideration. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com More than h... | They are: United Therapeutics (NASDAQ:UTHR) Novo Nordisk (NYSE:NVO) Dr Reddy’s Laboratories (NYSE:RDY) AbbVie (NYSE:ABBV) Eli Lilly & Co (NYSE:LLY) Zoetis (NYSE:ZTS) Horizon Therapeutics (NASDAQ:HZNP) Let’s look at what makes each worth your consideration. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com More than h... | They are: United Therapeutics (NASDAQ:UTHR) Novo Nordisk (NYSE:NVO) Dr Reddy’s Laboratories (NYSE:RDY) AbbVie (NYSE:ABBV) Eli Lilly & Co (NYSE:LLY) Zoetis (NYSE:ZTS) Horizon Therapeutics (NASDAQ:HZNP) Let’s look at what makes each worth your consideration. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com More than h... | They are: United Therapeutics (NASDAQ:UTHR) Novo Nordisk (NYSE:NVO) Dr Reddy’s Laboratories (NYSE:RDY) AbbVie (NYSE:ABBV) Eli Lilly & Co (NYSE:LLY) Zoetis (NYSE:ZTS) Horizon Therapeutics (NASDAQ:HZNP) Let’s look at what makes each worth your consideration. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com More than h... |
24,473 | 2020-07-14 00:00:00 UTC | Bill Gross predicts value outperforms growth, based on rates correlation | ABBV | https://www.nasdaq.com/articles/bill-gross-predicts-value-outperforms-growth-based-on-rates-correlation-2020-07-14 | null | null | By Kate Duguid
NEW YORK, July 14 (Reuters) - Billionaire investor Bill Gross is predicting that value stocks like IBM IBM.N and Altria Group MO.N are likely to fare better than growth stocks like Apple AAPL.O or Amazon.com AMZN.O in the near term, due to a correlation with real interest rates.
U.S. real yields - which ... | Gross said that as well as IBM and Altria, he likes stocks such as midstream company Enterprise Products Partners EPD.N and pharmaceutical giant AbbVie ABBV.N. U.S. real yields - which adjust for inflation - have been declining in response to the Federal Reserve's aggressive monetary actions over the past few months to... | Gross said that as well as IBM and Altria, he likes stocks such as midstream company Enterprise Products Partners EPD.N and pharmaceutical giant AbbVie ABBV.N. By Kate Duguid NEW YORK, July 14 (Reuters) - Billionaire investor Bill Gross is predicting that value stocks like IBM IBM.N and Altria Group MO.N are likely to ... | Gross said that as well as IBM and Altria, he likes stocks such as midstream company Enterprise Products Partners EPD.N and pharmaceutical giant AbbVie ABBV.N. By Kate Duguid NEW YORK, July 14 (Reuters) - Billionaire investor Bill Gross is predicting that value stocks like IBM IBM.N and Altria Group MO.N are likely to ... | Gross said that as well as IBM and Altria, he likes stocks such as midstream company Enterprise Products Partners EPD.N and pharmaceutical giant AbbVie ABBV.N. By Kate Duguid NEW YORK, July 14 (Reuters) - Billionaire investor Bill Gross is predicting that value stocks like IBM IBM.N and Altria Group MO.N are likely to ... |
24,474 | 2020-07-13 00:00:00 UTC | Notable Monday Option Activity: GPI, ISRG, ABBV | ABBV | https://www.nasdaq.com/articles/notable-monday-option-activity%3A-gpi-isrg-abbv-2020-07-13 | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Group 1 Automotive, Inc. (Symbol: GPI), where a total volume of 3,292 contracts has been traded thus far today, a contract volume which is representative of approximately 329,200 underlying shares (give... | Particularly high volume was seen for the $65 strike call option expiring January 15, 2021, with 9,802 contracts trading so far today, representing approximately 980,200 underlying shares of ABBV. Below is a chart showing ISRG's trailing twelve month trading history, with the $600 strike highlighted in orange: And AbbV... | Below is a chart showing ISRG's trailing twelve month trading history, with the $600 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 62,802 contracts thus far today. That number of contracts represents approximately 6.3 million underlying shares, working out to a sizeable 85.... | Below is a chart showing ISRG's trailing twelve month trading history, with the $600 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 62,802 contracts thus far today. That number of contracts represents approximately 6.3 million underlying shares, working out to a sizeable 85.... | Particularly high volume was seen for the $65 strike call option expiring January 15, 2021, with 9,802 contracts trading so far today, representing approximately 980,200 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $65 strike highlighted in orange: For the v... |
24,475 | 2020-07-10 00:00:00 UTC | Ex-Dividend Reminder: AbbVie, American Financial Group and Pennymac Mortgage Investment Trust | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-abbvie-american-financial-group-and-pennymac-mortgage-investment | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/20, AbbVie Inc (Symbol: ABBV), American Financial Group Inc (Symbol: AFG), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 ... | As a percentage of ABBV's recent stock price of $97.61, this dividend works out to approximately 1.21%, so look for shares of AbbVie Inc to trade 1.21% lower — all else being equal — when ABBV shares open for trading on 7/14/20. If they do continue, the current estimated yields on annualized basis would be 4.84% for Ab... | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/20, AbbVie Inc (Symbol: ABBV), American Financial Group Inc (Symbol: AFG), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 ... | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/20, AbbVie Inc (Symbol: ABBV), American Financial Group Inc (Symbol: AFG), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 ... | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/20, AbbVie Inc (Symbol: ABBV), American Financial Group Inc (Symbol: AFG), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. As a percentage of ABBV's recent stock price of $97.... |
24,476 | 2020-07-10 00:00:00 UTC | Botox, Keytruda Get FDA Approval For New Uses, BVXV Abuzz, First Droopy Eyelid Treatment Is Here | ABBV | https://www.nasdaq.com/articles/botox-keytruda-get-fda-approval-for-new-uses-bvxv-abuzz-first-droopy-eyelid-treatment-is | null | null | (RTTNews) - Today's Daily Dose brings you news about Altimmune's AdCOVID vaccine, the growing list of approved indications for AbbVie's Botox, an update on Aldeyra's Dry Eye disease drug candidate Reproxalap and FDA approval of Merck's Keytruda for yet another indication.
Read on…
1. FDA Approves Expanded Use of AbbVie... | BOTOX, developed by Allergan, an AbbVie (ABBV) company, received its first FDA approval in 1989 for two rare eye muscle disorders - blepharospasm and strabismus in adults. (RTTNews) - Today's Daily Dose brings you news about Altimmune's AdCOVID vaccine, the growing list of approved indications for AbbVie's Botox, an up... | (RTTNews) - Today's Daily Dose brings you news about Altimmune's AdCOVID vaccine, the growing list of approved indications for AbbVie's Botox, an update on Aldeyra's Dry Eye disease drug candidate Reproxalap and FDA approval of Merck's Keytruda for yet another indication. FDA Approves Expanded Use of AbbVie's Botox The... | (RTTNews) - Today's Daily Dose brings you news about Altimmune's AdCOVID vaccine, the growing list of approved indications for AbbVie's Botox, an update on Aldeyra's Dry Eye disease drug candidate Reproxalap and FDA approval of Merck's Keytruda for yet another indication. FDA Approves Expanded Use of AbbVie's Botox The... | (RTTNews) - Today's Daily Dose brings you news about Altimmune's AdCOVID vaccine, the growing list of approved indications for AbbVie's Botox, an update on Aldeyra's Dry Eye disease drug candidate Reproxalap and FDA approval of Merck's Keytruda for yet another indication. FDA Approves Expanded Use of AbbVie's Botox The... |
24,477 | 2020-07-09 00:00:00 UTC | 3 Top Biotech Stocks to Watch in July | ABBV | https://www.nasdaq.com/articles/3-top-biotech-stocks-to-watch-in-july-2020-07-09 | null | null | Between erratic market conditions, risk-fraught clinical trials, and unpredictable drug development pipelines, biotech investors know that with some stocks, discretion is the better part of valor. Nonetheless, July is a critical month for several leading biotech companies, and there's a lot that investors need to know ... | Editas has no products approved for sale, but it has posted year-over-year quarterly revenue growth of 176.6% thanks to its numerous preclinical development collaborations with companies like Abbvie. Between erratic market conditions, risk-fraught clinical trials, and unpredictable drug development pipelines, biotech i... | Editas has no products approved for sale, but it has posted year-over-year quarterly revenue growth of 176.6% thanks to its numerous preclinical development collaborations with companies like Abbvie. If Moderna's COVID-19 trial proceeds and reports favorable results, even with the recent troubling delay, its 47.7% year... | Editas has no products approved for sale, but it has posted year-over-year quarterly revenue growth of 176.6% thanks to its numerous preclinical development collaborations with companies like Abbvie. Sangamo inches closer to the market with its gene therapy for hemophilia Gene therapy company Sangamo Therapeutics (NASD... | Editas has no products approved for sale, but it has posted year-over-year quarterly revenue growth of 176.6% thanks to its numerous preclinical development collaborations with companies like Abbvie. The delay is related to Moderna's dosing protocol, but it's unclear if it means that the company's phase 2 results were ... |
24,478 | 2020-07-09 00:00:00 UTC | AbbVie : FDA Oks Expanded BOTOX Label For Treatment Of Pediatric Patients With Spasticity | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-fda-oks-expanded-botox-label-for-treatment-of-pediatric-patients-with-spasticity | null | null | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration approved a supplemental Biologics License Application or sBLA that supports expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity cau... | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration approved a supplemental Biologics License Application or sBLA that supports expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity cau... | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration approved a supplemental Biologics License Application or sBLA that supports expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity cau... | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration approved a supplemental Biologics License Application or sBLA that supports expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity cau... | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration approved a supplemental Biologics License Application or sBLA that supports expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity cau... |
24,479 | 2020-07-08 00:00:00 UTC | AbbVie Remains One of the Safest Pharma Investments You Can Make | ABBV | https://www.nasdaq.com/articles/abbvie-remains-one-of-the-safest-pharma-investments-you-can-make-2020-07-08 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When it comes to biotechnology market investing, sometimes it’s best just to de-risk your portfolio by sticking with well-known firms like AbbVie (NYSE:ABBV). There’s no perfectly safe investment, but among pharmaceutical plays, AbbVie stock involves less r... | Specifically, the FDA approved AbbVie’s supplemental biologics license application allowing Botox to be prescribed for specified instances of the “signs and symptoms of detrusor (bladder muscle) overactivity associated with an underlying neurologic condition” in patients aged five through 17. InvestorPlace - Stock Mark... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to biotechnology market investing, sometimes it’s best just to de-risk your portfolio by sticking with well-known firms like AbbVie (NYSE:ABBV). There’s no perfectly safe investment, but among pharmaceutical plays, AbbVie stock involves less r... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to biotechnology market investing, sometimes it’s best just to de-risk your portfolio by sticking with well-known firms like AbbVie (NYSE:ABBV). AbbVie Stock at a Glance An argument could be made, based on the price action alone, that ABBV is ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to biotechnology market investing, sometimes it’s best just to de-risk your portfolio by sticking with well-known firms like AbbVie (NYSE:ABBV). Plus, there’s no shortage of trading volume when it comes to ABBV stock. After regulators approved... |
24,480 | 2020-07-08 00:00:00 UTC | Better Buy: AbbVie vs. Biogen | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-biogen-2020-07-08 | null | null | AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two drugmakers that have moved in opposite directions on the stock market of late. While AbbVie has rebounded nicely from the market crash since late March -- with its stock up by 11.7% year to date as of this writing -- shares of Biogen have lost altitude since early A... | AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two drugmakers that have moved in opposite directions on the stock market of late. While AbbVie has rebounded nicely from the market crash since late March -- with its stock up by 11.7% year to date as of this writing -- shares of Biogen have lost altitude since early A... | By contrast, I expect AbbVie to continue growing its revenue and earnings, paying off its debt, and rewarding shareholders by way of strong and growing dividends from here on out. AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two drugmakers that have moved in opposite directions on the stock market of late. While A... | While AbbVie has rebounded nicely from the market crash since late March -- with its stock up by 11.7% year to date as of this writing -- shares of Biogen have lost altitude since early April or so, and are down by 10.7% since the beginning of the year. Biogen's debt-to-asset ratio of 22.8% is also much better than Abb... | For that reason, I think AbbVie will perform better on the stock market than Biogen, which makes it the better of these two healthcare stocks to buy right now. AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two drugmakers that have moved in opposite directions on the stock market of late. While AbbVie has rebounded ... |
24,481 | 2020-07-07 00:00:00 UTC | 4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX | ABBV | https://www.nasdaq.com/articles/4-top-stock-trades-for-wednesday%3A-lvgo-wmt-abbv-nvax-2020-07-07 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
After a strong trading day on Monday, investors used Tuesday as a way to digest the gains. Let’s look at a few top stock trades as we near mid-week.
Top Stock Trades for Tomorrow No. 1: Livongo (LVGO)
Click to Enlarge
Source: Chart courtesy of StockCharts... | Click to Enlarge Source: Chart courtesy of StockCharts.com Remember when we were looking at AbbVie (NYSE:ABBV) to make a nice move higher? 3: AbbVie (ABBV) The post 4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX appeared first on InvestorPlace. | The post 4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX appeared first on InvestorPlace. 3: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of StockCharts.com Remember when we were looking at AbbVie (NYSE:ABBV) to make a nice move higher? | The post 4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX appeared first on InvestorPlace. 3: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of StockCharts.com Remember when we were looking at AbbVie (NYSE:ABBV) to make a nice move higher? | The post 4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX appeared first on InvestorPlace. 3: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of StockCharts.com Remember when we were looking at AbbVie (NYSE:ABBV) to make a nice move higher? |
24,482 | 2020-07-07 00:00:00 UTC | AbbVie Stands to Benefit from Affluenza | ABBV | https://www.nasdaq.com/articles/abbvie-stands-to-benefit-from-affluenza-2020-07-07 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
For pharmaceutical giant AbbVie (NYSE:ABBV), the novel coronavirus couldn’t go away fast enough. Though AbbVie stock is obviously related to the suddenly in-demand healthcare space, the underlying company isn’t a play on the Covid-19 pandemic. In fact, the ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips For pharmaceutical giant AbbVie (NYSE:ABBV), the novel coronavirus couldn’t go away fast enough. Though AbbVie stock is obviously related to the suddenly in-demand healthcare space, the underlying company isn’t a play on the Covid-19 pandemic. Source: Piotr... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips For pharmaceutical giant AbbVie (NYSE:ABBV), the novel coronavirus couldn’t go away fast enough. With the coronavirus seemingly under control, investors began bidding up AbbVie stock. Though AbbVie stock is obviously related to the suddenly in-demand health... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips For pharmaceutical giant AbbVie (NYSE:ABBV), the novel coronavirus couldn’t go away fast enough. Though AbbVie stock is obviously related to the suddenly in-demand healthcare space, the underlying company isn’t a play on the Covid-19 pandemic. AbbVie Stock ... | Even more problematic for AbbVie stock is that hospitalizations are on the rise. Perhaps this is the new way to approach AbbVie stock. InvestorPlace - Stock Market News, Stock Advice & Trading Tips For pharmaceutical giant AbbVie (NYSE:ABBV), the novel coronavirus couldn’t go away fast enough. |
24,483 | 2020-07-07 00:00:00 UTC | 3 Best-Performing Dividend Aristocrats in the First Half of 2020: Are They Buys Now? | ABBV | https://www.nasdaq.com/articles/3-best-performing-dividend-aristocrats-in-the-first-half-of-2020%3A-are-they-buys-now-2020 | null | null | Claiming impressive track records of 25 or more consecutive years of dividend increases wasn't enough to translate to solid performances during the first half of 2020. Even with the overall market rebound in the second quarter, more than twice as many Dividend Aristocrats were in negative territory year to date after t... | The solid first-half jump stemmed in part from AbbVie easily beating Wall Street's Q1 revenue and earnings estimates. AbbVie AbbVie (NYSE: ABBV) trailed Lowe's in terms of stock performance during the first half of the year with a gain of 11%. Including its time as part of parent Abbott Labs (NYSE: ABT), AbbVie has inc... | AbbVie AbbVie (NYSE: ABBV) trailed Lowe's in terms of stock performance during the first half of the year with a gain of 11%. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie. Including its time as part of parent Abbott Labs (NYSE: ABT), AbbVie has increased its dividend ... | AbbVie AbbVie (NYSE: ABBV) trailed Lowe's in terms of stock performance during the first half of the year with a gain of 11%. Including its time as part of parent Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for 47 years. The solid first-half jump stemmed in part from AbbVie easily beating Wall Street's Q... | AbbVie AbbVie (NYSE: ABBV) trailed Lowe's in terms of stock performance during the first half of the year with a gain of 11%. Including its time as part of parent Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for 47 years. The solid first-half jump stemmed in part from AbbVie easily beating Wall Street's Q... |
24,484 | 2020-07-06 00:00:00 UTC | Royalty Pharma Stock Is Likely to Reach New Highs in the Coming Years | ABBV | https://www.nasdaq.com/articles/royalty-pharma-stock-is-likely-to-reach-new-highs-in-the-coming-years-2020-07-06 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Royalty Pharma (NASDAQ:RPRX) started trading on the NASDAQ June 16. It has been the largest initial public offering so far in 2020. Royalty Pharma offered 77.7 million shares, which was 7 million higher than initially planned. RPRX stock was priced at $28. ... | Some of the companies it partners with are AbbVie (NASDAQ:ABBV), Biogen (NASDAQ:BIIB), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), and Vertex Pharmaceuticals (NASDAQ:VRTX). According to a 2013 study by Andrew Lo and Sourya V. Naraharisetti of MIT: “new alternative investment companies have emerged to bridge the bio... | Some of the companies it partners with are AbbVie (NASDAQ:ABBV), Biogen (NASDAQ:BIIB), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), and Vertex Pharmaceuticals (NASDAQ:VRTX). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Royalty Pharma (NASDAQ:RPRX) started trading on the NASDAQ June 16. A Closer Loo... | Some of the companies it partners with are AbbVie (NASDAQ:ABBV), Biogen (NASDAQ:BIIB), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), and Vertex Pharmaceuticals (NASDAQ:VRTX). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Royalty Pharma (NASDAQ:RPRX) started trading on the NASDAQ June 16. A Closer Loo... | Some of the companies it partners with are AbbVie (NASDAQ:ABBV), Biogen (NASDAQ:BIIB), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), and Vertex Pharmaceuticals (NASDAQ:VRTX). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Royalty Pharma (NASDAQ:RPRX) started trading on the NASDAQ June 16. And that wou... |
24,485 | 2020-07-05 00:00:00 UTC | Got $5,000? Buy These 3 High-Yield Dividend Stocks That Are Money Machines | ABBV | https://www.nasdaq.com/articles/got-%245000-buy-these-3-high-yield-dividend-stocks-that-are-money-machines-2020-07-05 | null | null | Wouldn't it be nice to invest in stocks and then simply sit back while the money flows in? You can do just that with dividend stocks.
Sure, some companies pay only puny dividends. Others are on such shaky ground that their dividends are in jeopardy. But there are stocks on the market that pay dividends that are both j... | AbbVie recently picked up a big legal victory that should allow it hold onto its U.S. market share for top-selling drug Humira for a few more years. AbbVie picked up several great products with the deal, notably including the blockbuster Botox franchise and antipsychotic drug Vraylar. AbbVie Richard Nixon was beginning... | Brookfield Infrastructure Partners Brookfield Infrastructure Partners (NYSE: BIP) hasn't been around long enough to rival AbbVie when it comes to consecutive years of dividend increases. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners,... | Brookfield Infrastructure Partners Brookfield Infrastructure Partners (NYSE: BIP) hasn't been around long enough to rival AbbVie when it comes to consecutive years of dividend increases. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners,... | But AbbVie can. AbbVie Richard Nixon was beginning his second term when AbbVie's (NYSE: ABBV) streak of annual dividend hikes began. And since being spun off from Abbott Labs in 2013, AbbVie has raised its dividend by a whopping 195%. |
24,486 | 2020-07-03 00:00:00 UTC | 5 High-Yield Dividend Stocks to Watch | ABBV | https://www.nasdaq.com/articles/5-high-yield-dividend-stocks-to-watch-2020-07-03 | null | null | In a world of low interest rates, investors have had to become creative to find yield. One of the places they've found cash returns is in dividend stocks, particularly those that offer a relatively high payout. However, the higher the yield, the more risk investors face.
Fortunately, some high-yield dividend stocks rem... | AbbVie AbbVie (NYSE: ABBV) spent most of its history as a subsidiary of Abbott Laboratories before becoming an independent company in 2013. AbbVie stock benefited from a five-year bull run in most of the last decade. ABBV data by YCharts AbbVie's prospects improved as it addressed that concern. | AbbVie AbbVie (NYSE: ABBV) spent most of its history as a subsidiary of Abbott Laboratories before becoming an independent company in 2013. AbbVie stock benefited from a five-year bull run in most of the last decade. ABBV data by YCharts AbbVie's prospects improved as it addressed that concern. | AbbVie AbbVie (NYSE: ABBV) spent most of its history as a subsidiary of Abbott Laboratories before becoming an independent company in 2013. AbbVie stock benefited from a five-year bull run in most of the last decade. ABBV data by YCharts AbbVie's prospects improved as it addressed that concern. | AbbVie AbbVie (NYSE: ABBV) spent most of its history as a subsidiary of Abbott Laboratories before becoming an independent company in 2013. AbbVie stock benefited from a five-year bull run in most of the last decade. ABBV data by YCharts AbbVie's prospects improved as it addressed that concern. |
24,487 | 2020-07-02 00:00:00 UTC | AbbVie Is Cheap and Pays an Attractive Yield | ABBV | https://www.nasdaq.com/articles/abbvie-is-cheap-and-pays-an-attractive-yield-2020-07-02 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie (NYSE:ABBV) stock is both cheap and has a very attractive dividend yield. In addition, this pharmaceutical company’s growth prospects are high, now that its purchase of Allergan is closed.
Source: Piotr Swat / Shutterstock.com
For example, the stock ... | AbbVie’s main revenue driver, up until its recent acquisition of Allergan, was Humira, a rheumatoid arthritis drug. So not only is AbbVie stock cheap with an attractive dividend yield, but it also has good upside potential. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV) stock is both ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV) stock is both cheap and has a very attractive dividend yield. According to Seeking Alpha, AbbVie has had a 20.86% dividend growth rate annually on a compounded basis. So not only is AbbVie stock cheap with an attractive dividend yield, bu... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV) stock is both cheap and has a very attractive dividend yield. Valuing AbbVie Stock Given that management clearly seems intent on growing its dividend, we can use this aspect of the return of capital to value AbbVie stock. The historical d... | According to Seeking Alpha, AbbVie has had a 20.86% dividend growth rate annually on a compounded basis. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV) stock is both cheap and has a very attractive dividend yield. For one, the dividend yield for ABBV stock is much higher than the aver... |
24,488 | 2020-07-01 00:00:00 UTC | Best ETFs for 2020: The AdvisorShares Vice ETF Bets Big on Booze | ABBV | https://www.nasdaq.com/articles/best-etfs-for-2020%3A-the-advisorshares-vice-etf-bets-big-on-booze-2020-07-01 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
This article is a part of InvestorPlace.com’s Best ETFs for 2020 contest. The InvestorPlace Staff’s pick for the contest is the AdvisorShares Vice ETF (NASDAQ:ACT).
When I initially chose the AdvisorShares Vice ETF (NASDAQ:ACT) for InvestorPlace.com’s Best ... | Where ACT’s Top Holdings Stand Today ACT’s current top five holdings are Thermo Fisher Scientific (NYSE:TMO), Boston Beer Company (NYSE:SAM), Abbvie (NYSE:ABBV), Abbott Labs (NYSE:ABT) and PerkinElmer (NYSE:PKI). ABBV, which recently received an upgrade to “outperform” from “market perform” from analysts at Atlantic Eq... | Where ACT’s Top Holdings Stand Today ACT’s current top five holdings are Thermo Fisher Scientific (NYSE:TMO), Boston Beer Company (NYSE:SAM), Abbvie (NYSE:ABBV), Abbott Labs (NYSE:ABT) and PerkinElmer (NYSE:PKI). ABBV, which recently received an upgrade to “outperform” from “market perform” from analysts at Atlantic Eq... | Where ACT’s Top Holdings Stand Today ACT’s current top five holdings are Thermo Fisher Scientific (NYSE:TMO), Boston Beer Company (NYSE:SAM), Abbvie (NYSE:ABBV), Abbott Labs (NYSE:ABT) and PerkinElmer (NYSE:PKI). ABBV, which recently received an upgrade to “outperform” from “market perform” from analysts at Atlantic Eq... | Where ACT’s Top Holdings Stand Today ACT’s current top five holdings are Thermo Fisher Scientific (NYSE:TMO), Boston Beer Company (NYSE:SAM), Abbvie (NYSE:ABBV), Abbott Labs (NYSE:ABT) and PerkinElmer (NYSE:PKI). ABBV, which recently received an upgrade to “outperform” from “market perform” from analysts at Atlantic Eq... |
24,489 | 2020-07-01 00:00:00 UTC | 2 Biotech Stocks That Could Soar in 2020 | ABBV | https://www.nasdaq.com/articles/2-biotech-stocks-that-could-soar-in-2020-2020-07-01 | null | null | Stocks in the biotechnology sector have outperformed the broader market year to date. Despite the market volatility throughout this year, there are still good prospects in this sector, especially in small-cap biotechnology stocks. These companies are often selling at attractive prices, and their cutting-edge research c... | Several companies are in the early and middle stages of drug development for MDS treatments, including AbbVie, argenx, Karyopharm Therapeutics, and Takeda Pharmaceuticals. Early studies of Atara's lead product candidate, tab-cel (tabelecleucel), have shown it to be effective in improving survival for patients with a de... | Several companies are in the early and middle stages of drug development for MDS treatments, including AbbVie, argenx, Karyopharm Therapeutics, and Takeda Pharmaceuticals. Early studies of Atara's lead product candidate, tab-cel (tabelecleucel), have shown it to be effective in improving survival for patients with a de... | Several companies are in the early and middle stages of drug development for MDS treatments, including AbbVie, argenx, Karyopharm Therapeutics, and Takeda Pharmaceuticals. The company is developing novel cancer therapeutics that target p53, a protein expressed from the TP53 gene, a common mutation seen across a range o... | Several companies are in the early and middle stages of drug development for MDS treatments, including AbbVie, argenx, Karyopharm Therapeutics, and Takeda Pharmaceuticals. Aprea Therapeutics Aprea Therapeutics (NASDAQ: APRE) is another under-the-radar pick poised to excel in the long run. The company is developing nove... |
24,490 | 2020-06-29 00:00:00 UTC | 4 Stocks to Buy With Dividends Yielding More Than 4% | ABBV | https://www.nasdaq.com/articles/4-stocks-to-buy-with-dividends-yielding-more-than-4-2020-06-30 | null | null | Stocks may have recovered most of what was lost in February and March, shortly after the novel coronavirus began to spread in the U.S., but few investors are naive enough to think the market and the economy are as strong as they were early this year. The recent bullishness is mostly founded on hopes for a quick recover... | AbbVie has its fair share of blockbusters Current dividend yield: 4.9% AbbVie (NYSE: ABBV) is among the several pharmaceutical names that have been caught up in the fervor linked to the race for a coronavirus vaccine. Fortunately for AbbVie and its shareholders, the company's portfolio was already impressive. Even Humi... | AbbVie has its fair share of blockbusters Current dividend yield: 4.9% AbbVie (NYSE: ABBV) is among the several pharmaceutical names that have been caught up in the fervor linked to the race for a coronavirus vaccine. Fortunately for AbbVie and its shareholders, the company's portfolio was already impressive. Even Humi... | AbbVie has its fair share of blockbusters Current dividend yield: 4.9% AbbVie (NYSE: ABBV) is among the several pharmaceutical names that have been caught up in the fervor linked to the race for a coronavirus vaccine. Fortunately for AbbVie and its shareholders, the company's portfolio was already impressive. Even Humi... | AbbVie has its fair share of blockbusters Current dividend yield: 4.9% AbbVie (NYSE: ABBV) is among the several pharmaceutical names that have been caught up in the fervor linked to the race for a coronavirus vaccine. Fortunately for AbbVie and its shareholders, the company's portfolio was already impressive. Even Humi... |
24,491 | 2020-06-29 00:00:00 UTC | HIV treatment found to have no benefit for hospitalised COVID-19 patients in trial | ABBV | https://www.nasdaq.com/articles/hiv-treatment-found-to-have-no-benefit-for-hospitalised-covid-19-patients-in-trial-2020-06 | null | null | Adds quote, detail, background
LONDON, June 29 (Reuters) - A combination of antiviral drugs used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large-scale randomised trial, British scientists said on Monday.
Scientists running the RECOVERY trial at the University of Oxford said that ... | AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. Adds quote, detail, background LONDON, June 29 (Reuters) - A combination of antiviral drugs used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large-scale randomised trial, ... | AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. Adds quote, detail, background LONDON, June 29 (Reuters) - A combination of antiviral drugs used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large-scale randomised trial, ... | AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. Adds quote, detail, background LONDON, June 29 (Reuters) - A combination of antiviral drugs used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large-scale randomised trial, ... | AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. Adds quote, detail, background LONDON, June 29 (Reuters) - A combination of antiviral drugs used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large-scale randomised trial, ... |
24,492 | 2020-06-29 00:00:00 UTC | Canada federal court dismisses drugmakers' plea challenging drug price rules | ABBV | https://www.nasdaq.com/articles/canada-federal-court-dismisses-drugmakers-plea-challenging-drug-price-rules-2020-06-29 | null | null | June 29 (Reuters) - The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade.
The court struck down one part of the new regulation, finding that us... | The plaintiffs included the Canadian units of Pfizer Inc PFE.N, AbbVie Corp ABBV.N, Amgen Inc AMGN.O, Bristol Myers Squibb Co BMY.N, AstraZeneca Plc AZN.L, Novartis AG NOVN.S and Eli Lilly and Co LLY.N. June 29 (Reuters) - The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian gov... | The plaintiffs included the Canadian units of Pfizer Inc PFE.N, AbbVie Corp ABBV.N, Amgen Inc AMGN.O, Bristol Myers Squibb Co BMY.N, AstraZeneca Plc AZN.L, Novartis AG NOVN.S and Eli Lilly and Co LLY.N. The court struck down one part of the new regulation, finding that using certain payments to third parties to determi... | The plaintiffs included the Canadian units of Pfizer Inc PFE.N, AbbVie Corp ABBV.N, Amgen Inc AMGN.O, Bristol Myers Squibb Co BMY.N, AstraZeneca Plc AZN.L, Novartis AG NOVN.S and Eli Lilly and Co LLY.N. June 29 (Reuters) - The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian gov... | The plaintiffs included the Canadian units of Pfizer Inc PFE.N, AbbVie Corp ABBV.N, Amgen Inc AMGN.O, Bristol Myers Squibb Co BMY.N, AstraZeneca Plc AZN.L, Novartis AG NOVN.S and Eli Lilly and Co LLY.N. June 29 (Reuters) - The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian gov... |
24,493 | 2020-06-27 00:00:00 UTC | 3 Top Pharma Stocks to Buy in a Recession | ABBV | https://www.nasdaq.com/articles/3-top-pharma-stocks-to-buy-in-a-recession-2020-06-27 | null | null | We've officially been in a recession in the U.S. since February, according to the National Bureau of Economic Research. Some pundits think that the economy will rebound quickly, and many stock traders appear to be in that camp, considering how the equities market has climbed back from its steep February-March plunge ov... | AbbVie Arguably the most attractive thing about AbbVie (NYSE: ABBV) is its outstanding dividend, which currently yields close to 4.9%. Including the time that it was part of Abbott Labs, AbbVie claims an impressive track record of 47 consecutive years of dividend increases. Of course, what makes AbbVie's nice dividends... | Good recession plays AbbVie, Bristol Myers Squibb, and Eli Lilly aren't totally immune to the effects of a recession. AbbVie Arguably the most attractive thing about AbbVie (NYSE: ABBV) is its outstanding dividend, which currently yields close to 4.9%. Including the time that it was part of Abbott Labs, AbbVie claims a... | See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie and Bristol Myers Squibb. AbbVie Arguably the most attractive thing about AbbVie (NYSE: ABBV) is its outstanding dividend, which currently yields close to 4.9%. Including the time that it was part of Abbott Labs, AbbVie cla... | In addition, AbbVie's recent acquisition of Allergan brought the blockbuster Botox franchise into its lineup, as well as a long list of other drugs. Good recession plays AbbVie, Bristol Myers Squibb, and Eli Lilly aren't totally immune to the effects of a recession. AbbVie Arguably the most attractive thing about AbbVi... |
24,494 | 2020-06-26 00:00:00 UTC | AbbVie: FDA Issues Complete Response Letter To BLA For Abicipar Pegol | ABBV | https://www.nasdaq.com/articles/abbvie%3A-fda-issues-complete-response-letter-to-bla-for-abicipar-pegol-2020-06-26 | null | null | (RTTNews) - Allergan, an AbbVie Company (ABBV), and Molecular Partners announced the FDA has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, an investigational DARPin therapy for patients with neovascular age-related macular degeneration.
The Response Letter indicates that the... | (RTTNews) - Allergan, an AbbVie Company (ABBV), and Molecular Partners announced the FDA has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, an investigational DARPin therapy for patients with neovascular age-related macular degeneration. AbbVie plans to meet with the FDA to d... | (RTTNews) - Allergan, an AbbVie Company (ABBV), and Molecular Partners announced the FDA has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, an investigational DARPin therapy for patients with neovascular age-related macular degeneration. AbbVie plans to meet with the FDA to d... | (RTTNews) - Allergan, an AbbVie Company (ABBV), and Molecular Partners announced the FDA has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, an investigational DARPin therapy for patients with neovascular age-related macular degeneration. AbbVie plans to meet with the FDA to d... | (RTTNews) - Allergan, an AbbVie Company (ABBV), and Molecular Partners announced the FDA has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, an investigational DARPin therapy for patients with neovascular age-related macular degeneration. AbbVie plans to meet with the FDA to d... |
24,495 | 2020-06-26 00:00:00 UTC | FDA Rejects AbbVie's Macular Degeneration Drug Abicipar Pegol | ABBV | https://www.nasdaq.com/articles/fda-rejects-abbvies-macular-degeneration-drug-abicipar-pegol-2020-06-26 | null | null | One of the potential growth drivers from AbbVie's (NYSE: ABBV) acquisition of Allergan was just shot down by the Food and Drug Administration. The agency issued a complete response letter (the FDA's euphemism for a rejection) for AbbVie's abicipar pegol, which Allergan and Switzerland-based Molecular Partners were deve... | The agency issued a complete response letter (the FDA's euphemism for a rejection) for AbbVie's abicipar pegol, which Allergan and Switzerland-based Molecular Partners were developing for wet age-related macular degeneration. "We are committed to working with the FDA to determine the appropriate next steps for abicipar... | The agency issued a complete response letter (the FDA's euphemism for a rejection) for AbbVie's abicipar pegol, which Allergan and Switzerland-based Molecular Partners were developing for wet age-related macular degeneration. One of the potential growth drivers from AbbVie's (NYSE: ABBV) acquisition of Allergan was jus... | The agency issued a complete response letter (the FDA's euphemism for a rejection) for AbbVie's abicipar pegol, which Allergan and Switzerland-based Molecular Partners were developing for wet age-related macular degeneration. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stoc... | * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! One of the potential growth drivers from AbbVie's (NYSE: ABBV) acquisition of Allergan was just shot down by the Food and Drug Administration. The agency issued a complete response le... |
24,496 | 2020-06-26 00:00:00 UTC | Molecular Partners's AbbVie-partnered eye drug gets FDA safety snub | ABBV | https://www.nasdaq.com/articles/molecular-partnerss-abbvie-partnered-eye-drug-gets-fda-safety-snub-2020-06-26 | null | null | ZURICH, June 26 (Reuters) - Swiss drugmaker Molecular Partners MOLN.S has suffered a setback after the U.S. Food and Drug Administration said the company's abicipar product for a blindness-causing eye disease had an unfavorable risk-benefit profile due to inflammation.
Molecular Partners, which with abicipar was aiming... | Molecular Partners, which with abicipar was aiming for its first commercial product, has partnered on the medicine for macular degeneration with AbbVie ABBV.N unit Allergan, and has been hoping a successful launch would help bring in milestone payments to help fund the Swiss company's other projects. "AbbVie plans to m... | Molecular Partners, which with abicipar was aiming for its first commercial product, has partnered on the medicine for macular degeneration with AbbVie ABBV.N unit Allergan, and has been hoping a successful launch would help bring in milestone payments to help fund the Swiss company's other projects. "AbbVie plans to m... | Molecular Partners, which with abicipar was aiming for its first commercial product, has partnered on the medicine for macular degeneration with AbbVie ABBV.N unit Allergan, and has been hoping a successful launch would help bring in milestone payments to help fund the Swiss company's other projects. "AbbVie plans to m... | Molecular Partners, which with abicipar was aiming for its first commercial product, has partnered on the medicine for macular degeneration with AbbVie ABBV.N unit Allergan, and has been hoping a successful launch would help bring in milestone payments to help fund the Swiss company's other projects. "AbbVie plans to m... |
24,497 | 2020-06-26 00:00:00 UTC | Molecular Partners hopes for COVID-19 rebound after eye drug failure | ABBV | https://www.nasdaq.com/articles/molecular-partners-hopes-for-covid-19-rebound-after-eye-drug-failure-2020-06-26 | null | null | By John Miller
ZURICH, June 26 (Reuters) - Molecular Partners MOLN.S aims to test its COVID-19 drug candidate on people later this year, Chief Executive Patrick Amstutz said on Friday, as the Swiss company hopes that project will help it recover from the failure of its eye drug abicipar.
The U.S. Food and Drug Administ... | Given abicipar's uncertain future -- AbbVie has pledged further talks with U.S. regulators -- the experimental drug against the new coronavirus has emerged as Molecular Partner's best hope for a quick rebound. Molecular Partners signed a deal in 2011 that made it eligible to future payments of up to around $1.5 billion... | Given abicipar's uncertain future -- AbbVie has pledged further talks with U.S. regulators -- the experimental drug against the new coronavirus has emerged as Molecular Partner's best hope for a quick rebound. Molecular Partners signed a deal in 2011 that made it eligible to future payments of up to around $1.5 billion... | Molecular Partners signed a deal in 2011 that made it eligible to future payments of up to around $1.5 billion from its partner AbbVie ABBV.N, but only if the drug was a success. Given abicipar's uncertain future -- AbbVie has pledged further talks with U.S. regulators -- the experimental drug against the new coronavir... | Molecular Partners signed a deal in 2011 that made it eligible to future payments of up to around $1.5 billion from its partner AbbVie ABBV.N, but only if the drug was a success. Given abicipar's uncertain future -- AbbVie has pledged further talks with U.S. regulators -- the experimental drug against the new coronavir... |
24,498 | 2020-06-26 00:00:00 UTC | IVW, ABBV, CHTR, COST: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/ivw-abbv-chtr-cost%3A-large-outflows-detected-at-etf-2020-06-26 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $103.3 million dollar outflow -- that's a 0.4% decrease week over week (from 134,650,000 to 134,150,000). Among... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Charter Communications Inc (Symbol: CHTR) is down about 0.8%, and Costco Wholesale Corp (Symbol: COST) is relatively unchanged. For a complete list of holdings, visit the IVW Holdings page » The chart below sho... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Charter Communications Inc (Symbol: CHTR) is down about 0.8%, and Costco Wholesale Corp (Symbol: COST) is relatively unchanged. For a complete list of holdings, visit the IVW Holdings page » The chart below sho... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Charter Communications Inc (Symbol: CHTR) is down about 0.8%, and Costco Wholesale Corp (Symbol: COST) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of E... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Charter Communications Inc (Symbol: CHTR) is down about 0.8%, and Costco Wholesale Corp (Symbol: COST) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of E... |
24,499 | 2020-06-25 00:00:00 UTC | August 7th Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/august-7th-options-now-available-for-abbvie-abbv-2020-06-25 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the August 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new August 7th contracts and identified one put and one call contract of particular interest.
The put contract... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $96.50 strike highlighted in red: Considering the fact that the $96.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possi... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $91.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $96.50 strike price has a current bid of $1.13. Below is a chart showing ABBV'... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new August 7th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $96.50 strike highlighted in red: Consideri... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.